var title_f12_52_13120="Coronoid fracture";
var content_f12_52_13120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Coronoid fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A 12-year-old boy with a swollen elbow was thought to have a radial neck fracture based on this lateral view.",
"    <br>",
"     (B) An oblique view shows that the bony fragment (arrow) comes from the coronoid process.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13120=[""].join("\n");
var outline_f12_52_13120=null;
var title_f12_52_13121="Staphylococcal scalded skin syndrome - trunk";
var content_f12_52_13121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcal scalded skin syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and desqaumation are present in this child with staphylococcal scalded skin syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13121=[""].join("\n");
var outline_f12_52_13121=null;
var title_f12_52_13122="Patient information: How to use your child’s dry powder inhaler (The Basics)";
var content_f12_52_13122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16116\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/19/306\">",
"         Dry powder inhalers",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/4/33858\">",
"         Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/22/30052\">",
"         Patient information: Medicines for asthma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44083\">",
"         Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/60/18374\">",
"         Patient information: Asthma treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/how-to-use-your-childs-dry-powder-inhaler-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11860585\">",
"      <span class=\"h1\">",
"       Are there different types of dry powder inhalers?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are 2 main types of dry powder inhalers (",
"      <a class=\"graphic graphic_picture graphicRef67084 \" href=\"UTD.htm?0/19/306\">",
"       picture 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Single-dose inhalers",
"       </li>",
"       <li>",
"        Multiple-dose inhalers",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The directions for the 2 types of inhalers are slightly different.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11860592\">",
"      <span class=\"h1\">",
"       How do I use my child&rsquo;s dry powder inhaler?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each dry powder inhaler has its own directions. Your doctor or nurse will show you how to use your child&rsquo;s inhaler. &nbsp;",
"     </p>",
"     <p>",
"      In general, these are the steps for using a dry powder inhaler:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Open the inhaler or take off the cover",
"       </li>",
"       <li>",
"        Load a dose of medicine:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        For single-dose inhalers, you load a dose by taking a pill out of its packaging and putting the pill into the inhaler. Then you need to push 1 or more buttons on the inhaler to poke holes in the pill.",
"       </li>",
"       <li>",
"        For multiple-dose inhalers, you load a dose by sliding a lever or twisting the bottom (or another part) of the inhaler.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hold the inhaler in the correct position &mdash; Some inhalers need to be held upright, but others need to be horizontal. Multiple-dose inhalers usually need to be horizontal.",
"       </li>",
"       <li>",
"        Have your child breathe out normally&mdash;but",
"        <strong>",
"         not",
"        </strong>",
"        into the inhaler",
"       </li>",
"       <li>",
"        Have your child put his or her mouth on the mouthpiece",
"       </li>",
"       <li>",
"        Have your child breathe in quickly and steadily, as deeply as possible",
"       </li>",
"       <li>",
"        Have your child remove his or her mouth from the mouthpiece and hold his or her breath for 5 to 10 seconds",
"       </li>",
"       <li>",
"        Have your child let his or her breath out&mdash;but",
"        <strong>",
"         not",
"        </strong>",
"        into the inhaler",
"       </li>",
"       <li>",
"        For single-dose inhalers, you need to open the inhaler, take out the used pill, and throw it away",
"       </li>",
"       <li>",
"        If your child is supposed to take 2 puffs of the inhaler, load another dose and have him or her repeat the steps above",
"       </li>",
"       <li>",
"        Close the inhaler or replace the cover or cap",
"       </li>",
"       <li>",
"        Have your child rinse out his or her mouth, and spit out the water",
"       </li>",
"       <li>",
"        Store the inhaler in a cool, dry place",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11860599\">",
"      <span class=\"h1\">",
"       Do I need to clean my child&rsquo;s inhaler?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Do",
"      <strong>",
"       not",
"      </strong>",
"      wash a dry powder inhaler with water or put it under water. If the mouthpiece gets dirty, you can wipe it with a dry cloth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11860606\">",
"      <span class=\"h1\">",
"       How do I know when my child&rsquo;s inhaler is empty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many dry powder inhalers come with a built-in dose counter. A counter keeps track of how many doses are left in the inhaler.",
"     </p>",
"     <p>",
"      When the counter reads 0 (zero), it&rsquo;s time to throw out the inhaler. That&rsquo;s because there is no more medicine in it. Make sure to have another inhaler on hand before the counter reads 0.",
"     </p>",
"     <p>",
"      If the inhaler doesn&rsquo;t have a built-in counter, you need to keep track of the number of doses left in the inhaler. Based on how often your child uses the inhaler, you can figure out when he or she will need a refill and write this date down.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11860613\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/4/33858?source=see_link\">",
"       Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       Patient information: Medicines for asthma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       Patient information: Asthma treatment in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/52/13122?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16116 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-256F03B06F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13122=[""].join("\n");
var outline_f12_52_13122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11860585\">",
"      Are there different types of dry powder inhalers?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11860592\">",
"      How do I use my child&rsquo;s dry powder inhaler?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11860599\">",
"      Do I need to clean my child&rsquo;s inhaler?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11860606\">",
"      How do I know when my child&rsquo;s inhaler is empty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11860613\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/19/306\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/4/33858?source=related_link\">",
"      Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13123="Kissing bug bites";
var content_f12_52_13123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous reactions to kissing bug bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneous reactions consisting of erythema and edema may develop at the site of kissing bug bites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Lynch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13123=[""].join("\n");
var outline_f12_52_13123=null;
var title_f12_52_13124="Occiput transverse position";
var content_f12_52_13124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occiput transverse position",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Edward R Yeomans, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Clint M Cormier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13124/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/52/13124/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fetuses enter the maternal pelvis in the occiput transverse (OT) position; left occiput transverse (LOT) is more common than right (ROT). With progressive descent, the occiput usually rotates either anteriorly or posteriorly. Only a few fetuses remain in OT position at complete cervical dilatation. Most of these fetuses will rotate to occiput anterior or posterior during maternal expulsive efforts.",
"   </p>",
"   <p>",
"    Of note, the diagnosis of occiput transverse position is unrelated to transverse lie, in which the long axis of the fetal body is perpendicular to that of the mother. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=see_link\">",
"     \"Management of the fetus in transverse lie\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERSISTENT OCCIPUT TRANSVERSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We define persistent OT position as an OT position that is maintained for an hour or more into the second stage of labor. There are no reliable data on the frequency of persistent OT, but it is uncommon.",
"   </p>",
"   <p>",
"    Some of these fetuses, usually the very small ones, deliver in the OT position, while others rotate anteriorly or posteriorly after the fetal head descends to the pelvic floor. Those that do not rotate and descend after one hour of active pushing can be divided into two subsets:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High transverse arrest (arrest above station +2 on a -5 cm to + 5 cm scale)",
"     </li>",
"     <li>",
"      Deep transverse arrest (arrest below station +2 on a -5 cm to + 5 cm scale)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent OT position is thought to result from constraint to rotation by the bony pelvis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate power from contractions and pushing to induce rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent OT is more common with the platypelloid or android pelvis (",
"    <a class=\"graphic graphic_figure graphicRef50612 graphicRef63123 \" href=\"UTD.htm?17/29/17881\">",
"     figure 1A-B",
"    </a>",
"    ). With a platypelloid pelvis, the long occipitofrontal diameter of the fetal head readily adapts to the long transverse axis of the maternal bony pelvis, resulting in OT position, and there may not be adequate room for subsequent anterior or posterior rotation. With an android pelvis, engagement occurs in the transverse position, but rotation either anteriorly or posteriorly is impeded by the forward inclination of the sacrum.",
"   </p>",
"   <p>",
"    Inadequate power can result in persistent OT because rotating the fetus from OT or OP to the more favorable OA position requires adequate force. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26742?source=see_link\">",
"     \"Mechanism of normal labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;OT position should be suspected if fetal descent is protracted or arrested, since malposition is a common reason for nonprogress in the second stage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link\">",
"     \"Abnormal labor: Protraction and arrest disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is based on findings from transvaginal digital examination. The fetal sagittal suture and fontanelles are palpable in the transverse diameter of the pelvis; the fetal ears can be palpated superiorly under the symphysis and inferiorly above the",
"    <span class=\"nowrap\">",
"     sacrum/coccyx.",
"    </span>",
"    If the occiput (posterior fontanelle) is on the mother&rsquo;s left side, the position is LOT (",
"    <a class=\"graphic graphic_figure graphicRef52247 \" href=\"UTD.htm?32/0/32783\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Anterior or posterior asynclitism, defined as rotation of the sagittal suture away from or toward the pubic symphysis, respectively, may result in misdiagnosis of OT as either OA or OP. If the diagnosis is uncertain after careful physical assessment, transabdominal ultrasound examination can be useful to confirm the position [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PERSISTENT OCCIPUT TRANSVERSE POSITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88682159\">",
"    <span class=\"h2\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hypocontractile uterine activity is present, contractions should be augmented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link&amp;anchor=H10#H10\">",
"     \"Abnormal labor: Protraction and arrest disorders\", section on 'Hypocontractile uterine activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link&amp;anchor=H17#H17\">",
"     \"Abnormal labor: Protraction and arrest disorders\", section on 'Oxytocin augmentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is",
"    <strong>",
"     any",
"    </strong>",
"    progress in descent and the fetal heart rate is reassuring, expectant management is the preferred option. Partial or complete rotation may still occur spontaneously. If subsequent intervention is required, it will be easier because of the lower station",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nontransverse position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98685989\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend cesarean delivery for management of high transverse arrest despite adequate uterine activity and maternal expulsive effort. Under very unusual circumstances, such as the sudden onset of severe fetal or maternal compromise, manual or instrumental rotation and extraction above +2 cm station may be attempted while simultaneously initiating preparations for a cesarean delivery in the event these maneuvers are unsuccessful.",
"   </p>",
"   <p>",
"    Cesarean delivery, manual rotation, and instrumental rotation are options for management of deep transverse arrest. If vaginal delivery is attempted, the clinician should be experienced in manual or instrumental rotation and the prerequisites for operative vaginal delivery should be met (eg, cervix is fully dilated, head is engaged, membranes are ruptured, fetal position is known, pelvis is adequate, patient consents). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link&amp;anchor=H4#H4\">",
"     \"Operative vaginal delivery\", section on 'Prerequisites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Manual rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If progress becomes arrested during expectant management, manual rotation is performed by grasping the fetal head with the operator's hand, placing the tips of the index and middle fingers along the lambdoid sutures, flexing and slightly dislodging the vertex, and then rotating the head preferably to the OA position between contractions via rotation of the operator's hand and forearm. Alternatively, the operator's thumb and fingers can be placed on the parietal bones to grasp the head, which is then rotated. The head may need to be held in place for a few contractions to prevent rotation back toward the transverse position.",
"   </p>",
"   <p>",
"    The effectiveness of manual rotation was illustrated in a retrospective cohort study that found patients who underwent a trial of manual rotation in the second stage of labor (n = 731) had significantly shorter second stage and a significantly higher rate of vaginal delivery than those who did not have a trial of manual rotation (n = 2527), although intervention was associated with an increased risk of cervical laceration (2.2 versus 1.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/4\">",
"     4",
"    </a>",
"    ]. For this reason, we prefer expectant management as long as labor is progressing. However, manual rotation should be attempted soon after arrest of descent because observational data suggest the procedure is more likely to be successful when performed before it is necessitated by failure of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manual rotation is more likely to be successful in parous than nulliparous women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Instrumental rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent OT position occurs infrequently and the performance of even easy instrumental deliveries in the United States is diminishing, thus many clinicians lack the training, experience, and sound clinical judgment that come with experience to perform a 90 degree rotation. Therefore, manual rotation should be attempted before instrumental rotation. Depending upon the clinician&rsquo;s operative vaginal delivery experience, a cesarean delivery or assistance by an obstetrician experienced with instrumental rotation is recommended. In the authors&rsquo; practice, we attempt expectant management, then manual rotation, before considering instrumental rotation.",
"   </p>",
"   <p>",
"    In the United States, vacuum extraction is now performed more than twice as often as forceps delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/7\">",
"     7",
"    </a>",
"    ]. Proper cup placement is essential and selection of an appropriate cup design for the clinical situation is important. A rigid vacuum cup is advantageous over a soft cup because it allows greater traction, which is often needed for rotation from OT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/8\">",
"     8",
"    </a>",
"    ]. A flexible stem permits placement and movement of the device within the limited space of the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/9\">",
"     9",
"    </a>",
"    ]. Anterior auto-rotation is most likely to occur when cup application and traction result in head flexion rather than deflexion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13124/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The vacuum extractor itself should not be manipulated to rotate the head. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=see_link\">",
"     \"Procedure for vacuum assisted operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If forceps are chosen, a conventional instrument (eg, Luikart or Tucker McLane) can be used, but the pelvic curve of such forceps is a disadvantage. We prefer Kielland forceps to manage persistent OT position. However, in the rare case of a platypelloid pelvis, Kielland forceps are contraindicated. One of us (EY) has used Barton forceps in this situation, but we acknowledge that few practitioners have experience with these forceps. Technical considerations regarding application, rotation, and traction with forceps are complex and beyond the scope of this topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent occiput transverse (OT) position is an OT position that persists for an hour or more after complete cervical dilatation. It results from either constraint to rotation to occiput anterior or occiput posterior by the bony pelvis or inadequate power. Arrest of descent is the major consequence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Persistent occiput transverse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For persistent OT position with progressive descent, we suggest expectant management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If hypocontractile uterine activity is present, contractions should be augmented with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management of persistent occiput transverse position'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      We recommend cesarean delivery for management of high transverse arrest that persists despite adequate uterine activity and maternal expulsive effort, except under rare circumstances. (See",
"      <a class=\"local\" href=\"#H98685989\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cesarean delivery, manual rotation, and instrumental rotation are options for management of deep transverse arrest. If vaginal delivery is attempted, the clinician should be experienced in manual or instrumental rotation and the prerequisites for operative vaginal delivery should be met. We would attempt manual rotation before instrumental rotation. (See",
"      <a class=\"local\" href=\"#H98685989\">",
"       'Cesarean delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual rotation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Instrumental rotation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/1\">",
"      Danforth DN. Transverse arrest. Clin Obstet Gynecol 1965; 8:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/2\">",
"      Sen&eacute;cal J, Xiong X, Fraser WD, Pushing Early Or Pushing Late with Epidural study group. Effect of fetal position on second-stage duration and labor outcome. Obstet Gynecol 2005; 105:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/3\">",
"      Sherer DM, Miodovnik M, Bradley KS, Langer O. Intrapartum fetal head position II: comparison between transvaginal digital examination and transabdominal ultrasound assessment during the second stage of labor. Ultrasound Obstet Gynecol 2002; 19:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/4\">",
"      Shaffer BL, Cheng YW, Vargas JE, Caughey AB. Manual rotation to reduce caesarean delivery in persistent occiput posterior or transverse position. J Matern Fetal Neonatal Med 2011; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/5\">",
"      Le Ray C, Serres P, Schmitz T, et al. Manual rotation in occiput posterior or transverse positions: risk factors and consequences on the cesarean delivery rate. Obstet Gynecol 2007; 110:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/6\">",
"      Shaffer BL, Cheng YW, Vargas JE, et al. Manual rotation of the fetal occiput: predictors of success and delivery. Am J Obstet Gynecol 2006; 194:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/7\">",
"      Kozak LJ, Weeks JD. U.S. trends in obstetric procedures, 1990-2000. Birth 2002; 29:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/8\">",
"      O'Mahony F, Hofmeyr GJ, Menon V. Choice of instruments for assisted vaginal delivery. Cochrane Database Syst Rev 2010; :CD005455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/9\">",
"      Vacca A. Operative vaginal delivery: clinical appraisal of a new vacuum extraction device. Aust N Z J Obstet Gynaecol 2001; 41:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/10\">",
"      Bird GC. The use of the vacuum extractor. Clin Obstet Gynaecol 1982; 9:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/11\">",
"      Bird GC. The importance of flexion in vacuum extractor delivery. Br J Obstet Gynaecol 1976; 83:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13124/abstract/12\">",
"      Vacca A. Vacuum-assisted delivery. Best Pract Res Clin Obstet Gynaecol 2002; 16:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4466 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13124=[""].join("\n");
var outline_f12_52_13124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERSISTENT OCCIPUT TRANSVERSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT OF PERSISTENT OCCIPUT TRANSVERSE POSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88682159\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98685989\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Manual rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Instrumental rotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4466\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4466|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/8/14468\" title=\"figure 1A\">",
"      Pelvic shapes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/16/11525\" title=\"figure 1B\">",
"      Diameters fetal head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/0/32783\" title=\"figure 2\">",
"      Occiput transverse position",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=related_link\">",
"      Management of the fetus in transverse lie",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26742?source=related_link\">",
"      Mechanism of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=related_link\">",
"      Procedure for vacuum assisted operative vaginal delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13125="Dialysis disequilibrium syndrome";
var content_f12_52_13125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dialysis disequilibrium syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13125/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13125/contributors\">",
"     Lionel U Mailloux, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13125/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13125/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13125/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13125/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/52/13125/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First described in 1962, the dialysis disequilibrium syndrome (DDS) is a central nervous system disorder described in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is characterized by neurologic symptoms of varying severity that are thought to be due primarily to cerebral edema.",
"   </p>",
"   <p>",
"    New patients just being started on hemodialysis are at greatest risk, particularly if the BUN is markedly elevated (above 175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 60",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Other predisposing factors include severe metabolic acidosis, older age, pediatric patients, and the presence of other central nervous system disease such as a preexisting seizure disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss dialysis disequilibrium syndrome. Issues related to mental status changes and acute problems during dialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11322?source=see_link\">",
"     \"Psychiatric illness in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of DDS are caused by water movement into the brain, leading to cerebral edema. Two theories have been proposed to explain why this occurs: a reverse osmotic shift induced by urea removal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]; and a fall in cerebral intracellular pH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reverse osmotic shift",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis rapidly removes small solutes such as urea, particularly in patients who have marked azotemia. The reduction in BUN lowers the plasma osmolality, thereby creating a transient osmotic gradient that promotes water movement into the cells. In the brain, this water shift produces cerebral edema and a variable degree of acute neurologic dysfunction. The loss of extracellular water can also cause extracellular volume depletion which can contribute to the development of hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenetic importance of urea in the DDS has been demonstrated by experiments in uremic rats [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In one report, for example, rapid dialysis lowered the BUN from 200 to 95",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (72 to 34",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in 90 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/3\">",
"     3",
"    </a>",
"    ]. This change was associated with a six percent increase in brain water. Neither undialyzed rats nor those rats dialyzed against a bath to which urea was added to prevent a fall in BUN developed cerebral edema. Furthermore, the retention of brain urea appears to be account for most of the increase in brain water [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urea is generally considered an \"ineffective\" osmole, because of its ability to permeate cell membranes. However, this effect may take several hours to reach completion. Thus, there is insufficient time for urea equilibration when hemodialysis rapidly reduces the BUN; as a result, urea transiently acts as an effective osmole, promoting water movement into the brain. In the above experiments, for example, the 53 percent acute reduction in BUN was only associated with a 13 percent reduction in brain urea nitrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intracerebral acidosis and idiogenic osmoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have suggested that the reverse urea effect cannot account for the development of cerebral edema in the DDS, since urea movement out of the brain is sufficiently rapid to prevent a large osmotic gradient between the brain and extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/2\">",
"     2",
"    </a>",
"    ]. They have proposed that a decrease in cerebral intracellular pH, occurring via an uncertain mechanism, is of primary importance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Both displacement of bound sodium and potassium by the excess hydrogen ions and enhanced production of organic acids can increase intracellular osmolality and promote water movement into the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, an increase in brain organic osmolytes has not been confirmed in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. In most reports, the reverse urea effect appears sufficient to explain most of dialysis disequilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic DDS refers to acute symptoms developing during or immediately after hemodialysis or the initiation of a continuous renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/8\">",
"     8",
"    </a>",
"    ]. Early findings include headache, nausea, disorientation, restlessness, blurred vision, and asterixis. More severely affected patients progress to confusion, seizures, coma, and even death. It is now recognized, however, that many milder signs and symptoms associated with dialysis &mdash; such as muscle cramps, anorexia, and dizziness developing near the end of a dialysis treatment &mdash; are also part of this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/2,6,9-12\">",
"     2,6,9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of DDS varies according to the patient population and the attention paid to the preventive measures described below. Severe DDS is now rare in adults because of the standard use of the preventive recommendations made below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of the above symptoms during dialysis is strongly suggestive of DDS. Nevertheless, there are a number of other disorders that must be excluded. These include uremia itself, subdural hematoma, cerebral infarction, intracerebral hemorrhage, meningitis, metabolic disturbances (hyponatremia, hypoglycemia), and drug-induced encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/6\">",
"     6",
"    </a>",
"    ]. Drug accumulation is a particular problem in renal failure with drugs that are normally excreted by the kidney. Discussions related to the diagnosis of these disorders in the dialysis population are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11322?source=see_link\">",
"     \"Psychiatric illness in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is the mainstay of therapy in the DDS, particularly in new dialysis patients who are at highest risk, or in patients who have extremely high BUN concentrations or neurologic symptoms. The initial dialyses should be gentle, but repeated frequently. The aim is a gradual reduction in BUN, which will be protective but may not prevent mild symptoms such as headache and malaise. Slow urea removal can be achieved by one of the following methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With hemodialysis, therapy can be initiated with two hours of dialysis at a relatively low blood flow rate of 150 to 250",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      with a small surface area dialyzer (0.9 to 1.2 m2), and concurrent rather than countercurrent blood and dialysate flow. This regimen, which is repeated daily for three or four days, is different from the standard every other day four-hour regimen at high flow rates. If the patient shows no signs of DDS, the blood flow rate can be increased by 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per treatment (up to 300 to 400",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and the duration of dialysis can be increased in 30 minute increments (up to four or more hours, as necessary for adequate solute removal).",
"     </li>",
"     <li>",
"      Patients who also have marked fluid overload can be treated with ultrafiltration (which removes less urea per unit time and does not change plasma osmolarity) followed by a short period of hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient can be started on peritoneal dialysis in which the low rate of peritoneal blood flow results in a urea clearance per unit time that is much lower than that with hemodialysis. The DDS has not been reported with continuous peritoneal dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/2,13\">",
"       2,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with extremely elevated BUN or neurologic symptoms, dialysis should be initiated as an inpatient, although there are no data that have demonstrated better outcomes with this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, symptoms of DDS are self-limited and usually dissipate within several hours. The management of mild nonspecific disequilibrium symptoms, such as nausea, vomiting, restlessness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    headache, is symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/14\">",
"     14",
"    </a>",
"    ]; however, in the acutely uremic patient with such symptoms who is undergoing dialysis, the blood flow rate should be slowed and consideration should be given to stopping the dialysis session [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dialysis is stopped in the patient with seizures, coma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obtundation. Patency of the airway should also be ensured [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/14\">",
"     14",
"    </a>",
"    ]. In this setting, causes of these symptoms other than severe DSS should be considered. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis and differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Severe DDS with seizures can be reversed more rapidly by raising the plasma osmolality with either 5 mL of 23 percent saline or 12.5 g of hypertonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . However both maneuvers may be ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/15\">",
"     15",
"    </a>",
"    ] and many dialysis units and hospitals have banned the use of 23 percent saline. Some physicians administer either 50 percent dextrose solution or 1.5 percent or 3.0 percent NaCl as alternatives to very hypertonic NaCl. Supportive care as described above is generally considered standard of care. A detailed discussion concerning the management of seizures in the patient undergoing hemodialysis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management is supportive in the patient with severe DSS and coma. In this setting, improvement should occur within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13125/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384094545\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dialysis disequilibrium syndrome (DDS) is characterized by neurologic symptoms that are thought to be due primarily to cerebral edema. New patients just being started on hemodialysis are at greatest risk, particularly if the blood urea nitrogen (BUN) is markedly elevated (above 175",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 60",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Other predisposing factors include severe metabolic acidosis, older age, pediatric patients, and the presence of other central nervous system disease such as a preexisting seizure disorder. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevailing theory to explain the cerebral edema that underlies DDS is that a rapid reduction in urea by hemodialysis lowers the plasma osmolality creating a transient osmotic gradient that promotes water movement into the cells. An alternative hypothesis is that a decrease in cerebral intracellular pH causes increased intracellular osmolality and promotes water movement into the brain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic DDS develops during or immediately after hemodialysis. Early findings include headache, nausea, disorientation, restlessness, blurred vision, and asterixis. More severely affected patients progress to confusion, seizures, coma, and even death. Milder signs and symptoms include muscle cramps, anorexia, and dizziness. The symptoms of DDS are self-limited and usually dissipate within several hours. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of DDS includes uremia itself, subdural hematoma, cerebral infarction, intracerebral hemorrhage, meningitis, metabolic disturbances (hyponatremia, hypoglycemia), and drug-induced encephalopathy. Drug accumulation is a particular problem in renal failure with drugs that are normally excreted by the kidney. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention is the mainstay of therapy in the DDS, particularly in new dialysis patients who are at highest risk, or in patients who have extremely high BUN concentrations or neurologic symptoms. The initial dialyses should achieve a gradual reduction in urea. Slow urea removal can be achieved by the following methods (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With hemodialysis, therapy can be initiated with two hours of dialysis at a relatively low blood flow rate of 150 to 250",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      with a small surface area dialyzer (0.9 to 1.2 m2), and concurrent rather than countercurrent blood and dialysate flow. This regimen is repeated daily for three or four days. If the patient shows no signs of DDS, the blood flow rate can be increased by 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per treatment (up to 300 to 400",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and the duration of dialysis can be increased in 30 minute increments (up to four or more hours, as necessary for adequate solute removal).",
"      <br/>",
"      <br/>",
"      Patients who also have marked fluid overload can be treated with ultrafiltration (which removes less urea per unit time) followed by a short period of hemodialysis.",
"     </li>",
"     <li>",
"      The patient can be started on peritoneal dialysis in which the low rate of peritoneal blood flow results in a urea clearance per unit time that is much lower than that with hemodialysis. The DDS has not been reported with continuous peritoneal dialysis.",
"     </li>",
"     <li>",
"      Among patients with extremely elevated BUN concentration or neurologic symptoms, dialysis should be initiated as an inpatient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of DDS depends upon the severity of symptoms (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with mild nonspecific symptoms, such as nausea, vomiting, restlessness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      headache, are treated symptomatically; however, for the acutely uremic patient with such symptoms who is undergoing dialysis, the blood flow rate should be slowed and consideration should be given to stopping the dialysis session.",
"     </li>",
"     <li>",
"      Dialysis should be stopped in the patient with seizures, coma,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      obtundation. Patency of the airway should also be ensured. In this setting, causes of these symptoms other than severe DSS should be considered.",
"     </li>",
"     <li>",
"      Severe DDS with seizures can be reversed more rapidly by raising the plasma osmolality with either 5 mL of 23 percent saline or 12.5 g of hypertonic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      . However both maneuvers may be ineffective and many dialysis units and hospitals have banned the use of 23 percent saline. Some physicians administer either 50 percent dextrose solution, or 1.5 percent or 3.0 percent NaCl as alternatives to very hypertonic NaCl. Supportive care as described above is generally considered standard of care.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/1\">",
"      KENNEDY AC, LINTON AL, EATON JC. Urea levels in cerebrospinal fluid after haemodialysis. Lancet 1962; 1:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/2\">",
"      Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/3\">",
"      Silver SM, DeSimone JA Jr, Smith DA, Sterns RH. Dialysis disequilibrium syndrome (DDS) in the rat: role of the \"reverse urea effect\". Kidney Int 1992; 42:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/4\">",
"      Silver SM, Sterns RH, Halperin ML. Brain swelling after dialysis: old urea or new osmoles? Am J Kidney Dis 1996; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/5\">",
"      Galons JP, Trouard T, Gmitro AF, Lien YH. Hemodialysis increases apparent diffusion coefficient of brain water in nephrectomized rats measured by isotropic diffusion-weighted magnetic resonance imaging. J Clin Invest 1996; 98:750.",
"     </a>",
"    </li>",
"    <li>",
"     Ali, II, Pirzada, NA. Neurologic complications associated with dialysis and chronic renal insufficiency. In: Principles and Practice of Dialysis, Henrich, WL (Ed), Lippincott, Williams and Wilkins, Philadelphia, 2004, p. 507.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/7\">",
"      Silver SM. Cerebral edema after rapid dialysis is not caused by an increase in brain organic osmolytes. J Am Soc Nephrol 1995; 6:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/8\">",
"      RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/9\">",
"      Pagel MD, Ahmad S, Vizzo JE, Scribner BH. Acetate and bicarbonate fluctuations and acetate intolerance during dialysis. Kidney Int 1982; 21:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/10\">",
"      Rodrigo F, Shideman J, McHugh R, et al. Osmolality changes during hemodialysis. Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol. Ann Intern Med 1977; 86:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/11\">",
"      Van Stone JC, Meyer R, Murrin C, Cook J. Hemodialysis with glycerol dialysate. Trans Am Soc Artif Intern Organs 1979; 25:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/12\">",
"      Glenn CM, Astley SJ, Watkins SL. Dialysis-associated seizures in children and adolescents. Pediatr Nephrol 1992; 6:182.",
"     </a>",
"    </li>",
"    <li>",
"     Kliger, AS. Complications of dialysis: Hemodialysis, peritoneal dialysis, CAPD. In: Fluid, Electrolyte and Acid-Base Disorders, Arieff, AI, DeFronzo, RA (Eds), Churchill-Livingstone, New York, 1985, p. 777.",
"    </li>",
"    <li>",
"     Bergman, H, Daugirdas, JT, Ing, TS. Complications during hemodialysis. In: Handbook of Dialysis, Daugirdas, JG, Blake, PG, Ing, TS, (Eds), Lippincott, Williams, and Wilkins, Philadelphia, 2001, p. 158.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13125/abstract/15\">",
"      Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol 2012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1851 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13125=[""].join("\n");
var outline_f12_52_13125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H384094545\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reverse osmotic shift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intracerebral acidosis and idiogenic osmoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384094545\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11322?source=related_link\">",
"      Psychiatric illness in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=related_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13126="Treatment and prognosis of spontaneous low cerebrospinal fluid pressure headache";
var content_f12_52_13126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of spontaneous low cerebrospinal fluid pressure headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13126/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13126/contributors\">",
"     Christina Sun-Edelstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13126/contributors\">",
"     Christine L Lay, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13126/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13126/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13126/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13126/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/52/13126/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production, absorption, and flow of cerebrospinal fluid (CSF) play key roles in the dynamics of intracranial pressure. Alterations in CSF pressure can lead to neurologic symptoms, the most common being headache. Most often, the headaches associated with low CSF pressure are orthostatic and occur after lumbar puncture, but similar headaches occur with spontaneous low CSF pressure due to spinal CSF leaks, and with CSF shunt overdrainage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous low CSF pressure headache is being recognized with increasing frequency. Orthostatic headache, low CSF pressure, and diffuse meningeal enhancement on brain magnetic resonance imaging (MRI) are the major features of the classic syndrome. However, some cases have nonorthostatic headache, normal CSF pressure, or no evidence of diffuse meningeal enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/2\">",
"     2",
"    </a>",
"    ]. As our understanding of this syndrome is still evolving, the terms \"low CSF pressure headache,\" \"spontaneous intracranial hypotension,\" \"spontaneous CSF leak,\" \"CSF hypovolemia,\" and \"CSF volume depletion\" tend to be used interchangeably.",
"   </p>",
"   <p>",
"    This topic will review the treatment and prognosis of spontaneous low CSF pressure headache. Other aspects of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-lumbar puncture headache is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"     \"Post-lumbar puncture headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of spontaneous low cerebrospinal fluid (CSF) pressure headache should be considered in patients who present with positional orthostatic headache, with or without associated symptoms, perhaps in the setting of minor trauma, and in the absence of a history of dural puncture or other cause of CSF fistula. Low CSF pressure headache following a lumbar puncture rarely creates a clinical dilemma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confirmation of the diagnosis requires evidence of low CSF pressure by magnetic resonance imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55516 \" href=\"UTD.htm?29/23/30068\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77679 \" href=\"UTD.htm?23/42/24227\">",
"     image 2",
"    </a>",
"    ) or lumbar puncture,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of a CSF leak on neuroimaging studies, mainly computed tomographic myelography or radioisotope cisternography.",
"   </p>",
"   <p>",
"    The diagnosis of spontaneous low CFS pressure headache is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural blood patching is the mainstay of treatment for spontaneous low cerebrospinal fluid (CSF) pressure headache [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"     3",
"    </a>",
"    ]. Although data are lacking, clinical experience suggests that some patients with spontaneous low CSF pressure headache improve without specific treatment, given enough time. However, in many instances intervention may be necessary, not only to speed recovery, but to reach full recovery.",
"   </p>",
"   <p>",
"    Unfortunately, no randomized clinical trials have evaluated the effectiveness of the various treatment strategies employed, and no definitive treatment protocols have been established. Initial therapy for most patients with a confirmed diagnosis of spontaneous low CSF pressure headache consists of conservative measures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epidural blood patch. For patients who fail adequate trials of conservative therapy and repeated epidural blood patch treatments, additional options include continuous epidural saline infusion, epidural fibrin glue, or surgical repair of the defect.",
"   </p>",
"   <p>",
"    Both epidural fibrin glue and surgical repair require definitive localization of the spinal CSF leak or leaks. This is usually accomplished with computed tomographic (CT) myelography or, less often, radioisotope cisternography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conservative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most conservative treatment for low pressure headache is avoidance of the upright position, with strict bed rest and the possible addition of analgesics. However, many patients are unable to comply with strict bed rest.",
"   </p>",
"   <p>",
"    Strategies aimed at restoring cerebrospinal fluid (CSF) volume include oral or intravenous hydration, high oral caffeine intake, and high salt intake. Use of an abdominal binder is an additional measure that may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While analgesics are often recommended as first-line treatment, generally, they provide little relief [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/5\">",
"     5",
"    </a>",
"    ]. Anecdotally, glucocorticoids have been reported to be of some benefit, but remain unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with uncomplicated spontaneous low CSF pressure headache of mild to moderate severity, we suggest use of conservative measures as initial therapy. Our preferred regimen consists of bed rest and generous caffeine intake. Approximately 200 to 300 mg of caffeine, given two to three times daily, generally provides short-term relief. Caffeinated beverages (eg, coffee or soda) or caffeine tablets can be used.",
"   </p>",
"   <p>",
"    Oral hydration is traditionally recommended but its effectiveness has not been demonstrated in clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/7\">",
"     7",
"    </a>",
"    ]. However, by the time that many patients with mild to moderate spontaneous low CSF pressure headache present to a neurologist, they have already had the headache for weeks to months, and conservative measures have failed. For those patients, epidural blood patch is recommended as soon as possible.",
"   </p>",
"   <p>",
"    Patients with severe headache should be treated initially with an epidural blood patch, as should patients with more serious associated symptoms (eg, diminished level of consciousness) related to distortion or compression of brain and spinal cord structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\", section on 'Associated symptoms and complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidural blood patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;When conservative treatment fails, epidural blood patch (EBP) is the treatment of choice. Epidural blood patch therapy involves the infusion of 10 to 20 cc of autologous blood into the epidural space [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism that accounts for the success of EBP is not completely understood, but the leading hypothesis is that EBP works initially through tamponade of the dural leak, and later by fibrin deposition and scar formation that is found within three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/4\">",
"     4",
"    </a>",
"    ]. The tamponade of the leak often results in an immediate improvement in symptoms.",
"   </p>",
"   <p>",
"    Few studies have investigated the effectiveness of EBP for spontaneous low CSF headache. The range of findings is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One early study found that EBP was 85 to 100 percent effective in the treatment of spontaneous low CSF pressure headache [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A later retrospective case series of 25 consecutive patients with spontaneous CSF leaks found a good response to the initial EBP in 9 (36 percent) of 25 patients and a good response to a second EBP in 5 (33 percent) of 15 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a series of 30 patients diagnosed with spontaneous low CSF pressure headache based upon clinical features, pain resolved completely with the first EBP in 17 patients (57 percent) and with a second EBP in six of nine patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies highlight the observation that approximately 50 percent of patients with spontaneous intracranial hypotension require more than one EBP treatment, and some patients may require up to four to six patches [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/6\">",
"     6",
"    </a>",
"    ]. Lumbar placement of the EBP can be effective even when the site of CSF leakage is above the site of the blood patch or is unknown. One study found that targeting the EBP to the level of the CSF leak (when known) was more effective than blind EBP at the lumbar level, but this finding is limited by methodologic limitations including the retrospective, nonrandom study design and small patient numbers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of EBP are uncommon but include back pain, radiculopathy, leg paresthesias, and fever.",
"   </p>",
"   <p>",
"    We recommend EBP for patients with spontaneous low CSF fluid headache who fail conservative treatment. We also recommend EBP as first-line therapy for patients who have severe headache or disabling symptoms of intracranial hypotension.",
"   </p>",
"   <p>",
"    The initial EBP treatment typically involves the infusion of 10 to 20 cc of autologous blood into the epidural space. A larger volume (20 to 100 mL) infusion is suggested if the initial blood patch is unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"     3",
"    </a>",
"    ]. With use of the higher volume infusion, a minimum of five days between blood patches is suggested because of the potential for an increased risk of complications including back pain and radiculopathy. In addition, some experts advise the use of different injection sites for repeated blood patches (eg, first at the thoracolumbar junction, then in the lower lumbar area) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epidural fibrin glue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural patching with fibrin glue at the site of the CSF leak has been used successfully in small numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Anecdotal evidence suggests that this method is effective, and thereby avoids surgery, in about one-third of patients who have failed epidural blood patch treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence of benefit in larger studies is needed before this technique can be routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/12\">",
"     12",
"    </a>",
"    ]. Nevertheless, some authorities favor the use of epidural fibrin glue in an effort to avoid surgery for patients with a clearly identified site of CSF leak who have failed an adequate trial of repeated EBP.",
"   </p>",
"   <p>",
"    Some commercially available fibrin sealant products contain bovine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    , an antifibrinolytic agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrin sealant\", section on 'Components of commercial and alternative preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of fibrin sealant is associated with a very low risk of anaphylaxis. However, repeated treatment with fibrin sealant containing bovine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    appears to be associated with a substantially increased risk of hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, patients selected for epidural fibrin glue treatment should be asked about possible previous exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    or fibrin sealant, since these agents have been used for hemostasis in various types of surgery (cardiac, transplantation, joint replacement, repair of splenic injury) and hemostatic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measures that may reduce the risk of anaphylaxis, although unproven, include treating multiple sites of CSF leak together rather than as staged procedures, waiting three to six months before repeating fibrin sealant treatment, and performing repeat treatment after prophylactic administration of glucocorticoids, H1 receptor antagonists, and hospital admission for observation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Continuous epidural infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;One method of restoring the intracranial CSF volume, and thereby reducing headache, is a continuous epidural infusion of saline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/16\">",
"     16",
"    </a>",
"    ]. This method has limited success, but it is suggested for patients who fail EBP if the site of the CSF leak cannot be identified. In addition, it may be useful as a temporizing measure when urgent treatment is needed (eg, because of stupor or coma) for those who fail EBP and are awaiting permanent repair of a CSF leak [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3,17\">",
"     3,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgical repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of a CSF leak may be required in some patients if nonsurgical therapies fail [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3,18\">",
"     3,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical methods involve the use of suture or metallic clips to ligate leaking meningeal diverticula [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/1,3,18\">",
"     1,3,18",
"    </a>",
"    ]. Dural tears and defects can be repaired with suture or with placement of a muscle pledget, Gelfoam,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrin glue.",
"   </p>",
"   <p>",
"    We suggest surgical repair only for patients with a clearly identified site of CSF leakage by neuroimaging (typically CT myelography) who have failed an adequate trial of repeated EBP. Surgical exploration alone appears to have a low yield for detecting the source of a CSF leak [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/18\">",
"     18",
"    </a>",
"    ]. We suggest obtaining surgical treatment from surgeons or centers with expertise in spinal surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The headache associated with low cerebrospinal fluid (CSF) pressure may resolve spontaneously within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/19\">",
"     19",
"    </a>",
"    ]. In some cases, it may last months, or in rare cases, years. However, intermittent headaches have been reported at intervals of weeks, months, or years, probably caused by intermittent CSF leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, some patients have persistent symptoms despite documented resolution of CSF leakage with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although only anecdotal data are available, low CSF pressure headache due to spinal CSF leak is estimated to reoccur in approximately 10 percent of patients regardless of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary data suggest that initial brain magnetic resonance imaging (MRI) findings may be helpful for predicting the outcome of spontaneous intracranial hypotension. In a referral center series of 33 patients with spontaneous spinal CSF leaks and intracranial hypotension, a good outcome was reported in 25 (97 percent) of 26 patients with an abnormal MRI versus 1 (14 percent) of 7 patients with a normal MRI, and the difference between these groups was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13126/abstract/20\">",
"     20",
"    </a>",
"    ]. However, it is unclear why a normal MRI was associated with a worse prognosis, and larger studies in more diverse patient populations are needed to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidural blood patch (EBP) therapy is the mainstay of treatment for spontaneous low cerebrospinal fluid (CSF) pressure headache. However, for patients with uncomplicated spontaneous low CSF pressure headache of mild to moderate severity, we suggest use of conservative measures as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preferred regimen consists of bed rest and generous caffeine intake. For patients who fail conservative treatment, we recommend EBP therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Conservative treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidural blood patch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have severe headache or disabling symptoms due to spontaneous low CSF pressure, we recommend EBP as initial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidural blood patch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is only anecdotal evidence that treatment with epidural fibrin glue is beneficial for spontaneous low CSF, and larger studies are needed before this technique can be routinely recommended. However, some experts favor the use of epidural fibrin glue in an effort to avoid surgery for patients with a clearly identified site of CSF leak who have failed an adequate trial of repeated EBP. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidural fibrin glue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with spontaneous low CSF pressure headache in whom the site of the CSF leak cannot be identified, we suggest continuous epidural infusion of saline or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Continuous epidural infusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with spontaneous low CSF pressure headache who have failed an adequate trial of repeated EBP and have a clearly identified site of CSF leakage, we suggest surgical repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgical repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low CSF pressure headache due to spinal CSF leak is estimated to reoccur in approximately 10 percent of patients regardless of treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of post-lumbar puncture headache is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"       \"Post-lumbar puncture headache\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/1\">",
"      Schievink WI, Reimer R, Folger WN. Surgical treatment of spontaneous intracranial hypotension associated with a spinal arachnoid diverticulum. Case report. J Neurosurg 1994; 80:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/2\">",
"      Mokri B. Spontaneous cerebrospinal fluid leaks: from intracranial hypotension to cerebrospinal fluid hypovolemia--evolution of a concept. Mayo Clin Proc 1999; 74:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/3\">",
"      Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA 2006; 295:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/4\">",
"      Marcelis J, Silberstein SD. Spontaneous low cerebrospinal fluid pressure headache. Headache 1990; 30:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/5\">",
"      Lipman IJ. Primary intracranial hypotension: the syndrome of spontaneous low cerebospinal fluid pressure with traction headache. Dis Nerv Syst 1977; 38:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/6\">",
"      Mokri B. Spontaneous intracranial hypotension. Curr Pain Headache Rep 2001; 5:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/7\">",
"      Mokri B. Low cerebrospinal fluid pressure syndromes. Neurol Clin 2004; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/8\">",
"      Gaukroger PB, Brownridge P. Epidural blood patch in the treatment of spontaneous low CSF pressure headache. Pain 1987; 29:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/9\">",
"      Sencakova D, Mokri B, McClelland RL. The efficacy of epidural blood patch in spontaneous CSF leaks. Neurology 2001; 57:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/10\">",
"      Berroir S, Loisel B, Ducros A, et al. Early epidural blood patch in spontaneous intracranial hypotension. Neurology 2004; 63:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/11\">",
"      Cho KI, Moon HS, Jeon HJ, et al. Spontaneous intracranial hypotension: efficacy of radiologic targeting vs blind blood patch. Neurology 2011; 76:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/12\">",
"      Crul BJ, Gerritse BM, van Dongen RT, Schoonderwaldt HC. Epidural fibrin glue injection stops persistent postdural puncture headache. Anesthesiology 1999; 91:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/13\">",
"      Schievink WI, Maya MM, Moser FM. Treatment of spontaneous intracranial hypotension with percutaneous placement of a fibrin sealant. Report of four cases. J Neurosurg 2004; 100:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/14\">",
"      Schievink WI, Georganos SA, Maya MM, et al. Anaphylactic reactions to fibrin sealant injection for spontaneous spinal CSF leaks. Neurology 2008; 70:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/15\">",
"      Beierlein W, Scheule AM, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 2005; 79:741.",
"     </a>",
"    </li>",
"    <li>",
"     Lay CL, Campbell JK, Mokri B. Low cerebrospinal fluid pressure headache. In: Headache, Goadsby PJ, Silberstein SD (Eds), Butterworth-Heinemann, Boston 1997. p.355.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/17\">",
"      Binder DK, Dillon WP, Fishman RA, Schmidt MH. Intrathecal saline infusion in the treatment of obtundation associated with spontaneous intracranial hypotension: technical case report. Neurosurgery 2002; 51:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/18\">",
"      Schievink WI, Morreale VM, Atkinson JL, et al. Surgical treatment of spontaneous spinal cerebrospinal fluid leaks. J Neurosurg 1998; 88:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/19\">",
"      Rando TA, Fishman RA. Spontaneous intracranial hypotension: report of two cases and review of the literature. Neurology 1992; 42:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13126/abstract/20\">",
"      Schievink WI, Maya MM, Louy C. Cranial MRI predicts outcome of spontaneous intracranial hypotension. Neurology 2005; 64:1282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3361 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13126=[""].join("\n");
var outline_f12_52_13126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conservative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidural blood patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epidural fibrin glue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Continuous epidural infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgical repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3361|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/23/30068\" title=\"diagnostic image 1\">",
"      MRI diffuse meningeal enhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/42/24227\" title=\"diagnostic image 2\">",
"      MRI brain sagging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13127="Amoxapine: Drug information";
var content_f12_52_13127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amoxapine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41604?source=see_link\">",
"    see \"Amoxapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5696595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Secondary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Outpatients: Initial: 50 mg 2-3 times/day; dose may be increased to 100 mg 2-3 times/day by the end of the first week, if tolerated. Usual effective dose: 200-300 mg/day; if 300 mg daily has been reached and maintained for at least 2 weeks and no response is observed, may further increase to 400 mg/day. Once an effective dose is reached, doses &le;300 mg may be given once daily at bedtime and doses &gt;300 mg/day should be divided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inpatients: Hospitalized patients refractory to antidepressant therapy (and no history of seizures) may be cautiously titrated to 600 mg/day in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Outpatients and Inpatients: Once symptoms are controlled, gradually decrease to lowest dose that will maintain remission.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Use caution or avoid in the elderly. Initial: 25 mg 2-3 times/day; dose may be increased to 50 mg 2-3 times/day by the end of the first week, if tolerated; usual effective dose: 100-150 mg/day; if dose is ineffective, may further increase cautiously to 300 mg/day; once an effective dose is reached, doses &le;300 mg may be given once daily at bedtime. Maintenance: Once symptoms are controlled, gradually decrease to the lowest dose that will maintain remission.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, amoxapine is primarily eliminated renally, and renal failure may develop in overdoses; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression (including endogenous, neurotic, psychotic, and reactive depression); treatment of depression accompanied by anxiety or agitation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amoxapine may be confused with amoxicillin, Amoxil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Asendin may be confused with aspirin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (14%), constipation (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, confusion, dizziness, EEG abnormalities, excitement, fatigue, headache, insomnia, nervousness, nightmares, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Edema, skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine: Prolactin levels increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, allergic reactions, diarrhea, extrapyramidal symptoms, fever, galactorrhea, hepatitis, hypertension, hypomania. impotence, incoordination, intraocular pressure increased, leukopenia, menstrual irregularity, mydriasis, neuroleptic malignant syndrome, numbness, painful ejaculation, paresthesia, photosensitivity, seizure, SIADH, syncope, tardive dyskinesia, testicular edema, tinnitus, urinary retention, vasculitis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amoxapine or any component of the formulation; use with or within 14 days of MAO inhibitors; acute recovery phase following myocardial infarction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Amoxapine is not FDA approved for use in pediatric patients.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is low). The risk for tardive dyskinesia (may be irreversible) increases with long-term treatment and higher cumulative doses. Therapy should be discontinued in any patient if signs/symptoms of tardive dyskinesia appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Amoxapine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria). May also have increased risk of adverse events, including tardive dyskinesia (particularly older women) and sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F134452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F134432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may inhibit the metabolism of some TCAs and clinical toxicity may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10912489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies; however, fetotoxic and embryotoxic effects were seen in some studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F134422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amoxapine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $61.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $99.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $166.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $78.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and pulse rate prior to and during initial therapy evaluate mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); ECG in older adults and patients with cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Asendin (ID);",
"     </li>",
"     <li>",
"      Defanyl (FR);",
"     </li>",
"     <li>",
"      Demolox (DK, IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces the reuptake of serotonin and norepinephrine. The metabolite, 7-OH-amoxapine has significant dopamine receptor blocking activity similar to haloperidol.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of antidepressant effect: Usually occurs after 1-2 weeks, but may require 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.9-1.2 L/kg; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized; hepatic hydroxylation produces two active metabolites, 7-hydroxyamoxapine (7-OH-amoxapine) and 8-hydroxyamoxapine (8-OH-amoxapine); metabolites undergo conjugation to form glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8 hours; 7-hydroxyamoxapine metabolite: 4-6 hours; 8-hydroxyamoxapine metabolite: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glassman AH and Preud'homme XA, &ldquo;Review of the Cardiovascular Effects of Heterocyclic Antidepressants,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1993, 54(Suppl):16-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107:623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard BE, &ldquo;Safety of Amoxapine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1989, 2(8666):808.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/52/13127/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schatzberg AF. &ldquo;Recent Developments in the Acute Somatic Treatment of Major Depression,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1992, 53(Suppl):20-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin&reg; in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8652 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-854D70C629-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13127=[""].join("\n");
var outline_f12_52_13127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5696595\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134457\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134438\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134439\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673161\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673162\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134411\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134396\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874549\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134415\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134465\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134455\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134419\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134400\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134452\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134405\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134432\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134406\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10912489\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134442\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134422\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134408\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539816\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134399\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134418\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8652|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41604?source=related_link\">",
"      Amoxapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13128="Technique for performing electroconvulsive therapy (ECT) in adults";
var content_f12_52_13128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Technique for performing electroconvulsive therapy (ECT) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13128/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13128/contributors\">",
"     Charles Kellner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13128/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13128/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/52/13128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroconvulsive therapy (ECT) is practiced widely in the United States and the rest of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/1\">",
"     1",
"    </a>",
"    ]. It is used mainly to treat severe depression, but is also indicated for patients with other conditions, including bipolar disorder, schizophrenia, schizoaffective disorder, delirium, and neuroleptic malignant syndrome.",
"   </p>",
"   <p>",
"    There is no question about the efficacy and safety of ECT. Nevertheless, it remains controversial and stigmatized because of misinformation and outdated perceptions about how the treatment is performed.",
"   </p>",
"   <p>",
"    The goal of ECT is to produce a generalized cerebral seizure under general anesthesia. The technique affects the rate of remission with ECT, which varies from 20 to 80 percent depending upon the procedures that are used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique for performing ECT is reviewed here. An overview of ECT, the indications for treating unipolar major depression with ECT, the efficacy of ECT for treating unipolar depression, and medical consultation for ECT are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"       \"Overview of electroconvulsive therapy (ECT) for adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link\">",
"       \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"       \"Medical consultation for electroconvulsive therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SETTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT is performed in a dedicated ECT treatment suite, a hospital post-anesthesia care unit, or an ambulatory surgery suite.",
"   </p>",
"   <p>",
"    ECT may be performed on an inpatient or outpatient basis, and there is an increasing trend toward outpatient ECT. Patients with severe medical or psychiatric illness may start ECT on an inpatient basis and as they improve, switch to outpatient treatment. Continuation and maintenance ECT are almost always given on an outpatient basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Continuation and maintenance ECT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRE-ECT ORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orders for each ECT treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No food or drink (NPO) after midnight",
"     </li>",
"     <li>",
"      Intravenous line",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient receives general anesthesia as part of ECT and thus should not eat solid food for six to eight hours prior to the procedure, and not drink clear liquids for two hours, except for necessary medications with a small sip of water [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The patient should empty his or her bladder before the treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT PROTOCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT is administered by a team that typically includes a psychiatrist, anesthesiologist, and nurse. Most patients are treated according to a protocol that addresses the following issues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient safety &mdash; Confirm the identity of the patient, that the patient is NPO, has taken necessary medications, and signed the informed consent form. In addition, the patient is monitored after the seizure for approximately 30 to 60 minutes.",
"     </li>",
"     <li>",
"      Equipment &mdash; ECT device, device to monitor vital signs and pulse oximetry, anesthesia equipment, nasal cannula to provide oxygen, nerve stimulator to assess degree of motor relaxation, electromyograph, blood pressure cuffs (arm and ankle)",
"     </li>",
"     <li>",
"      Medications &mdash; Anesthetic, neuromuscular blocker. Anticholinergic and cardiovascular medication as indicated",
"     </li>",
"     <li>",
"      Documentation &mdash; Record vital signs, ECT device settings, and duration of seizure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic functions monitored during ECT include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vital signs",
"     </li>",
"     <li>",
"      Blood oxygen saturation",
"     </li>",
"     <li>",
"      Cardiac rhythms (ECG)",
"     </li>",
"     <li>",
"      Electrical activity of the brain (EEG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, electromyography (EMG) may be performed to evaluate the electrical activity of the muscles and a nerve stimulator may be used to monitor the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (used to reduce tonic-clonic contractions).",
"   </p>",
"   <p>",
"    EEG monitoring is crucial because it enables the practitioner to confirm that a cerebral seizure has occurred and has ended in a timely fashion. The EEG is typically recorded with one or two channels, from right and left frontal and mastoid positions (",
"    <a class=\"graphic graphic_figure graphicRef51413 \" href=\"UTD.htm?41/16/42241\">",
"     figure 1",
"    </a>",
"    ). ECT devices display the EEG tracing on a paper record",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computer screen, and may also provide information about the adequacy of the recorded seizure by means of automated indices. Despite the device interpretation, interpretation of the EEG remains an important skill for the ECT practitioner.",
"   </p>",
"   <p>",
"    EMG is generally recorded from the right foot in order to measure the length of the motor component of the seizure. This corresponds with the possible use of right unilateral electrode placement. A blood pressure cuff is placed and inflated on the right ankle to prevent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    from entering the foot. An alternative to using the EMG is to simply place a blood pressure cuff on the ankle and have a member of the treatment team watch the foot after the electric stimulus is administered and record the duration of tonic-clonic contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ELECTRODE PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electric current used to induce the seizure passes briefly through the brain via two electrodes applied to the scalp (using either the adhesive type of electrode or hand-held type). Psychiatrists typically position the stimulating electrodes in one of three ways (",
"    <a class=\"graphic graphic_figure graphicRef77514 \" href=\"UTD.htm?20/33/21010\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral",
"     </li>",
"     <li>",
"      Right unilateral",
"     </li>",
"     <li>",
"      Bifrontal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bilateral, also known as bitemporal, is the original, \"gold standard\" placement. One electrode is placed on each temple, with the center of the electrode placed 2 to 3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the head. Bilateral placement has the greatest antidepressant efficacy and quickest speed of response, but may cause the most memory impairment.",
"   </p>",
"   <p>",
"    Right unilateral electrode placement consists of placing one electrode on the right temple and one on the scalp, just to the right of the vertex (d'Elia placement). Specifically, one electrode is positioned as in bilateral on the right side, and the center of the other electrode is placed 2 to 3 cm to the right side of the vertex of the skull. This technique avoids initial stimulation of the left cerebral hemisphere, which is usually dominant for language functions. Right unilateral may be slightly less effective for some patients, but generally causes fewer adverse cognitive effects such as memory impairment.",
"   </p>",
"   <p>",
"    Bifrontal consists of placing each electrode on the forehead above the outer canthus of each eye. The center of each stimulating electrode is placed 4 to 5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils. Some clinicians believe that bifrontal is as effective as bilateral with the same cognitive impairment as right unilateral, although there is a much smaller evidence base for this technique. Nonetheless, it is used widely in clinical practice.",
"   </p>",
"   <p>",
"    A meta-analysis of 22 randomized trials (1408 patients) found that although bilateral ECT was superior to unilateral ECT for treating depression, the difference was small and likely to be of only minimal to moderate clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent randomized trial compared the three electrode placements in 230 patients with unipolar or bipolar major depression and found no statistically significant difference in the proportion of patients who remitted with bilateral, bifrontal, or right unilateral placement (64 versus 60 versus 55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Bilateral ECT caused a significantly better response early in the course of treatment, compared with bifrontal and right unilateral. In addition, there was little difference in the adverse cognitive effects of each placement, a somewhat surprising finding that may be attributable to the stimulus dosing of right unilateral at six times seizure threshold. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Stimulus dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral ECT in more urgent clinical situations",
"     </li>",
"     <li>",
"      Right unilateral ECT when there is a significant concern about minimizing retrograde amnesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients whose symptoms do not respond to right unilateral ECT can be switched to bilateral. We suggest doing so after three to five treatments, depending upon the patient's clinical status and preference.",
"   </p>",
"   <p>",
"    Clinicians should avoid stimulating over or adjacent to a skull defect, regardless of the type of electrode placement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the pre-ECT evaluation should address whether there is a history of skull fracture, which may indicate the need for skull radiographs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Pre-ECT evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STIMULUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years it was assumed that the electric stimulus was relevant only for its ability to elicit a grand mal seizure. It is now clear that the type and intensity of the stimulus contribute to the efficacy and adverse cognitive effects of ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stimulus type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of stimulus used in contemporary ECT devices is a brief pulse (0.5 to 2.0 milliseconds) or ultra-brief pulse (&lt;0.5 milliseconds) waveform. Brief pulse is considered standard, but there is accumulating evidence that ultra-brief pulse stimuli may cause less cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/9\">",
"     9",
"    </a>",
"    ]. The outmoded sine wave form of stimulus causes more cognitive impairment and should no longer be used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Stimulus dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intensity or dose of the electric stimulus affects efficacy, speed of response, and adverse cognitive effects. Stimulus intensity is usually described in terms of seizure threshold, which may be estimated or determined empirically at the first treatment session [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Establishing the seizure threshold is accomplished by initially setting the ECT device to use a small amount of energy to induce the seizure. If this dose does not produce a seizure, the device is then set at an incrementally higher dose in an attempt to induce a seizure. This process is repeated until a seizure occurs, which then establishes the seizure threshold.",
"   </p>",
"   <p>",
"    The stimulus dose depends upon the electrode placement. The suggested stimulus dose for bilateral or bifrontal ECT is 1.5 to 2 times seizure threshold. The suggested dose for right unilateral is 6 times seizure threshold, based upon data showing that seizures need to be elicited with stimuli that are several times greater than seizure threshold for unilateral placement to be maximally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Electrode placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The higher dose required for right unilateral occasionally becomes a problem because ECT devices manufactured in the United States are limited to a charge output of 600 millicoulombs by Food and Drug Administration regulations. This prevents a small number of patients with a relatively high seizure threshold from being treated at fully six times seizure threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is common for seizure threshold to increase during an acute course of ECT. This may necessitate incrementally increasing the dose of the electric stimulus periodically.",
"   </p>",
"   <p>",
"    Clinicians should follow the specific instructions of the ECT device as specified by the manufacturer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANESTHESIA TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of anesthesia for ECT is to provide the patient with a safe, comfortable experience. The anesthesiologist preoxygenates the patient and administers medications to induce unconsciousness and to relax or paralyze skeletal muscles. In addition, an anticholinergic drug may be given prior to ECT to prevent bradycardia or asystole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preoxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is preoxygenated with supplemental oxygen (2",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    via nasal cannula while the procedure is being set up, with the goal of maintaining oxygen saturation at or near 100 percent. This makes ECT safer with fewer adverse effects than either a spontaneous (epileptic) seizure or ECT in the past. In addition, the patient is often hyperventilated immediately prior to delivering the electrical stimulus. This induces cerebral hypocarbia, which increases seizure intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anticholinergic medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication with an anticholinergic agent, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    (0.2 mg, IV) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (0.4 mg, IV), is often used to prevent vagally-mediated bradycardia and excess oral and respiratory secretions. Bradycardia is most common at the first treatment, when there is a greater chance of administering a subconvulsive stimulus that leads to vagal outflow unopposed by subsequent sympathetic activity from a seizure. Anticholinergics may cause or exacerbate tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anesthetic medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anesthesia should not interfere with inducing an effective grand mal seizure. The induction agent of choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    , generally given at a dose of 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is a commonly used alternative, but it is more potently anticonvulsant than methohexital and may reduce seizure duration in some circumstances. Other induction agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/15\">",
"     15",
"    </a>",
"    ]. There has been interest in the use of ultrashort-acting narcotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    to replace at least some of the standard induction agent, but this has not been widely adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Muscle relaxation medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal muscle relaxation is used during ECT to minimize the motor seizure and prevent musculoskeletal injury. This is particularly important for patients with osteoporosis. The standard agent for muscle relaxation is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , a depolarizing neuromuscular blocker, given at a dose of 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    via intravenous infusion. Muscle relaxation subsides promptly with discontinuing the infusion.",
"   </p>",
"   <p>",
"    Nondepolarizing muscle relaxants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    , mivacurium, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    are used only in special circumstances when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    cannot be used. Such circumstances include pseudocholinesterase deficiency, severe neuromuscular disease or injury (quadriplegia, amyotrophic lateral sclerosis, or muscular dystrophy), severe muscular rigidity, or recent severe and widespread burns [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2,15\">",
"     2,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudocholinesterase is needed to metabolize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , and its absence will lead to prolonged apnea and muscle relaxation. A pseudocholinesterase level (also referred to as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35410?source=see_link\">",
"     dibucaine",
"    </a>",
"    number) is measured only in patients with a personal or family history of prolonged apnea following exposure to muscle relaxants.",
"   </p>",
"   <p>",
"    It is important to ascertain that the patient is unconscious before proceeding with the muscle relaxant, to avoid unnecessary patient distress. The patient is rendered apneic by the muscle relaxant, at which point the anesthesiologist provides ventilation by bag and mask with 100 percent oxygen.",
"   </p>",
"   <p>",
"    The sufficiency of muscle relaxation is determined using a nerve stimulator and observing the decrement and eventual disappearance of response. In addition, the clinician can assess knee and plantar withdrawal reflexes, and can simultaneously observe for fasciculations in the calves and left foot and wait until they subside, usually within one to two minutes of administering the muscle relaxant. Perfusion of the right foot with the muscle relaxant is prevented by an inflated blood pressure cuff on the right ankle.",
"   </p>",
"   <p>",
"    Muscle contractions often occur despite the use of a muscle relaxant. As an example, masseter muscles may contract, and thus it is important to remove dentures, if present, prior to administering the electric stimulus. In addition, a member of the treatment team should insert a bite block to protect the teeth, making sure that the tongue is pushed inferiorly and posteriorly in the mouth, and that the chin is held firmly against the bite block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiovascular medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic cardiac medications immediately before or during ECT may be administered for the purpose of blunting the hypertensive, tachycardic response to the seizure and reducing the risk of myocardial ischemia. The most commonly used drugs in this situation are beta blockers. The use of beta blockers for this purpose is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link&amp;anchor=H12#H12\">",
"     \"Medical consultation for electroconvulsive therapy\", section on 'Prophylactic beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SEIZURE DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimal duration for a therapeutic ECT seizure is 15 seconds. Beyond this, the efficacy of ECT is not related to seizure duration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most therapeutic ECT seizures last 15 to 70 seconds on EEG recording. The recording typically lasts 10 to 30 percent longer than the motor seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Problems with ECT include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Missed seizures &mdash; the electrical stimulus does not induce a seizure",
"     </li>",
"     <li>",
"      Short seizures &mdash; last less than 15 seconds",
"     </li>",
"     <li>",
"      Prolonged seizures &mdash; last longer than two to three minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Short seizures may be subtherapeutic, and prolonged seizures may be associated with increased cognitive impairment.",
"   </p>",
"   <p>",
"    Missed seizures should be followed by a brief (eg, 20 seconds) period of hyperventilation and restimulation at an incrementally higher stimulus dose. Short seizures should be followed by a longer period of hyperventilation (eg, 60 seconds) and restimulation at an incrementally higher stimulus dose.",
"   </p>",
"   <p>",
"    A prolonged seizure is a potentially serious complication that needs to be recognized and treated promptly. We suggest terminating seizures that last longer than 180 seconds. The standard procedure is to administer one-half the induction dose of the anesthetic (when it is either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ). Alternatively, a dose of benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    5 mg IV) may be given [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Managing missed or short seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several procedures to use for persistent missed or short seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/2,3,18,19\">",
"     2,3,18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreasing or discontinuing anticonvulsant mood stabilizers and benzodiazepines, if possible",
"     </li>",
"     <li>",
"      Hyperventilating the patient before and during the seizure",
"     </li>",
"     <li>",
"      Decreasing the anesthetic dose to the minimum compatible with full unconsciousness",
"     </li>",
"     <li>",
"      Switching anesthetic to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      (0.15 to 0.30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV), which are less anticonvulsant than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"       methohexital",
"      </a>",
"     </li>",
"     <li>",
"      Intravenous caffeine has been used to prolong seizures, but is no longer recommended because its clinical benefits are uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13734882\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many aspects of administering ECT to pregnant patients are comparable to the technique used for patients who are not pregnant. As an example, the electrical stimulus dose is not adjusted for pregnancy because it is not clear that pregnancy changes seizure threshold during ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Electrical stimulus dosing is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Stimulus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, ECT technique for pregnant patients should be modified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid hyperventilating the patient (hyperventilation can diminish fetal oxygenation by decreasing placental blood flow and reducing the dissociation of oxygen from hemoglobin)",
"     </li>",
"     <li>",
"      Hydrate patients with intravenous fluids prior to each ECT treatment to minimize the risk of premature contractions",
"     </li>",
"     <li>",
"      For pregnancies between 12 and 23 weeks of gestation, document the fetal heart rate before and after each ECT treatment",
"     </li>",
"     <li>",
"      When the gestational age exceeds 20 weeks, place a wedge beneath the patient&rsquo;s right hip during each ECT treatment to displace the uterus from the aorta and vena cava and thus optimize maternal venous return, cardiac output, blood pressure, and uterine blood flow.",
"     </li>",
"     <li>",
"      For pregnancies &ge;24 weeks of gestation (the fetus is considered viable if born at this gestation age), continuously monitor the fetal heart rate and uterine activity for 30 to 60 minutes before and after each ECT treatment. A clinician with experience placing monitoring devices and interpreting these tracings should be available.",
"     </li>",
"     <li>",
"      Administer ECT at facilities with resources for treating obstetric and neonatal emergencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnant patients are at increased risk for gastric reflux and aspiration pneumonitis, which can be minimized with one or more of the following measures during each ECT treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13128/abstract/20-22,24\">",
"     20-22,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withhold anticholinergic drugs &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       Glycopyrrolate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      may decrease lower esophageal sphincter tone and thus increase reflux. However, for pregnant patients who require an anticholinergic drug to prevent excessive bradycardia, we suggest glycopyrrolate, which does not cross the placenta as readily as atropine. Use of anticholinergic medication during ECT is discussed elsewhere in this topic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anticholinergic medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administer one or two of the following drugs 40 to 60 minutes prior to the procedure to mitigate the effects of aspiration if it occurs: a nonparticulate antacid (eg, sodium citrate 30 mL orally), a histamine-2 receptor antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      50 mg intravenously), a proton pump inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      20 mg orally), or prokinetic drug (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      10 mg intravenously)",
"     </li>",
"     <li>",
"      Intubate the patient, especially at week 25 of gestation and beyond &ndash; Intubation is the least preferred option for managing aspiration risk because of its associated morbidity, especially during pregnancy due to weight gain, edema, and hypervascularity; even minor trauma can lead to profuse bleeding. Intubation of pregnant patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34248?source=see_link\">",
"       \"Airway management of pregnant women at delivery\"",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The teratogenic risks and postnatal effects of ECT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link&amp;anchor=H1561541#H1561541\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Electroconvulsive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37106?source=see_link\">",
"       \"Patient information: Electroconvulsive therapy (ECT) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/50/37664?source=see_link\">",
"       \"Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTSIDE SOURCES OF PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the requirements for obtaining informed consent for ECT is that patients receive adequate information about the procedure. Additional written material is available for patients and family members to augment discussions with the psychiatrist at",
"    <a class=\"external\" href=\"file://jama.ama-assn.org/cgi/reprint/285/10/1390\">",
"     file://jama.ama-assn.org/cgi/reprint/285/10/1390",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Educational material explaining ECT is also available as part of a document entitled \"Brain Stimulation Therapies\" that is published by the National Institute of Mental Health. This publication can be obtained through a toll-free number, 866-615-646, or online at the Web site",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml\">",
"     file://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml",
"    </a>",
"    . The Web site also provides information about depression in language intended for the lay public.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of ECT is to produce a generalized cerebral seizure under general anesthesia. The procedures that are used to perform ECT affect the rate of remission, which varies from 20 to 80 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient receives general anesthesia as part of ECT and thus should not eat solid food for six to eight hours prior to the procedure, and not drink clear liquids for 2 hours, except for necessary medications with a small sip of water. The patient should empty his or her bladder before the treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pre-ECT orders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The equipment used for the procedure includes an ECT device to deliver the stimulus and record an EEG, device to monitor vital signs and pulse oximetry, anesthesia equipment, oxygen via nasal cannula, nerve stimulator to assess degree of motor relaxation, electromyograph, blood pressure cuffs (arm and ankle). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The electric current used to induce the seizure passes briefly through the brain via two electrodes applied to the scalp. Psychiatrists typically position the stimulating electrodes in one of three ways: bilateral, right unilateral, or bifrontal. We suggest bilateral ECT in more urgent clinical situations, and right unilateral ECT when there is a significant concern about minimizing retrograde amnesia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Electrode placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of stimulus used in contemporary ECT devices is a brief pulse (0.5 to 2.0 milliseconds) or ultra-brief pulse (&lt;0.5 milliseconds) waveform. Brief pulse is considered standard, but there is accumulating evidence that ultra-brief pulse stimuli may cause less cognitive impairment. The outmoded sine wave form of stimulus causes more cognitive impairment and should no longer be used. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stimulus type'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Stimulus dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of the electric stimulus is usually estimated empirically at the first treatment session. If the initial small dose does not produce a seizure, incrementally higher doses are given until a seizure occurs. The suggested stimulus dose at subsequent treat sessions for bilateral ECT is 1.5 to 2 times seizure threshold, and for right unilateral is 6 times seizure threshold. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stimulus type'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Stimulus dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient is preoxygenated with supplemental oxygen (2",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      via nasal cannula while the procedure is being set up. Premedication with an anticholinergic agent, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      (0.2 mg, IV) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      (0.4 mg, IV), is often used to prevent vagally-mediated bradycardia. Prophylactic beta blockers may be administered immediately before or during ECT to blunt the hypertensive, tachycardic response to the seizure. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preoxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anesthesia of choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"       methohexital",
"      </a>",
"      , generally given at a dose of 0.75 to 1",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      Other induction agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"       thiopental",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anesthetic medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skeletal muscle relaxation is used during ECT to minimize the motor seizure and prevent musculoskeletal injury. The standard agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , given at a dose of 0.75 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      via intravenous infusion. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Muscle relaxation medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The minimal duration for a therapeutic ECT seizure is 15 seconds. Beyond this, the efficacy of ECT is not related to seizure duration. Most therapeutic ECT seizures last 15 to 70 seconds on EEG recording. Problems with ECT include seizures that are missed, short, or prolonged. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Seizure duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECT technique is modified for pregnant patients. (See",
"      <a class=\"local\" href=\"#H13734882\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/1\">",
"      Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007; 357:1939.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.",
"    </li>",
"    <li>",
"     Kellner, CH, Pritchett, JT, Beale, MD, Coffey, CE. Handbook of ECT, American Psychiatric Press, Inc., Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/4\">",
"      UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/5\">",
"      Kellner CH, Knapp R, Husain MM, et al. Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry 2010; 196:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/6\">",
"      Scott AI. Electroconvulsive therapy, practice and evidence. Br J Psychiatry 2010; 196:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/7\">",
"      Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000; 57:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/8\">",
"      Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology 2007; 32:244.",
"     </a>",
"    </li>",
"    <li>",
"     Kellner, C. Ultrabrief Pulse Right Unilateral ECT: A New Standard of Care?. Psychiatric Times 2009; 26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/10\">",
"      Petrides G, Fink M. The \"half-age\" stimulation strategy for ECT dosing. Convuls Ther 1996; 12:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/11\">",
"      Petrides G, Braga RJ, Fink M, et al. Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral electroconvulsive therapy: a report from CORE. J ECT 2009; 25:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/12\">",
"      McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry 2000; 57:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/13\">",
"      Lisanby SH, Devanand DP, Nobler MS, et al. Exceptionally high seizure threshold: ECT device limitations. Convuls Ther 1996; 12:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/14\">",
"      Bergsholm P, Gran L, Bleie H. Seizure duration in unilateral electroconvulsive therapy. The effect of hypocapnia induced by hyperventilation and the effect of ventilation with oxygen. Acta Psychiatr Scand 1984; 69:121.",
"     </a>",
"    </li>",
"    <li>",
"     Kellner, C, Li, D, Maron, L. Anesthesia for electroconvulsive therapy. In: Electroconvulsive and Neuromodulation Therapies, Swartz, C (Ed), Cambridge University Press, Cambridge 2009. p.412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/16\">",
"      Sullivan PM, Sinz EH, Gunel E, Kofke WA. A retrospective comparison of remifentanil versus methohexital for anesthesia in electroconvulsive therapy. J ECT 2004; 20:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/17\">",
"      Mayur PM, Gangadhar BN, Janakiramaiah N, Subbakrishna DK. Motor seizure monitoring during electroconvulsive therapy. Br J Psychiatry 1999; 174:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/18\">",
"      Datto C, Rai AK, Ilivicky HJ, Caroff SN. Augmentation of seizure induction in electroconvulsive therapy: a clinical reappraisal. J ECT 2002; 18:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/19\">",
"      Devanand DP, Decina P, Sackeim HA, Prudic J. Status epilepticus following ECT in a patient receiving theophylline. J Clin Psychopharmacol 1988; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/20\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/21\">",
"      Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45:444.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/23\">",
"      Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13128/abstract/24\">",
"      Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71:235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1712 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13128=[""].join("\n");
var outline_f12_52_13128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SETTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRE-ECT ORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT PROTOCOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSIOLOGIC MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ELECTRODE PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STIMULUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stimulus type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Stimulus dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANESTHESIA TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preoxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anticholinergic medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anesthetic medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Muscle relaxation medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiovascular medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SEIZURE DURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Managing missed or short seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13734882\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTSIDE SOURCES OF PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1712|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/16/42241\" title=\"figure 1\">",
"      EEG recording leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/33/21010\" title=\"figure 2\">",
"      ECT stimulating electrodes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34248?source=related_link\">",
"      Airway management of pregnant women at delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/50/37664?source=related_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37106?source=related_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13129="Catheter ablation for ventricular arrhythmias";
var content_f12_52_13129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catheter ablation for ventricular arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13129/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13129/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13129/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/52/13129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapy for symptomatic and life-threatening ventricular arrhythmias includes use of the implantable cardioverter-defibrillator (ICD), catheter ablation, and, at times, cardiac surgery. Pharmacologic therapy of ventricular arrhythmias is limited by high failure rates, potential for proarrhythmia, and frequent toxicity. At present, the ICD provides the foundation for treating the majority of patients with clinically significant ventricular arrhythmias, particularly when associated with structural heart disease.",
"   </p>",
"   <p>",
"    The role of catheter ablation in the treatment of ventricular arrhythmias will be reviewed here. Most studies of ablative therapy have used radiofrequency (RF) catheter ablation; other ablative techniques have only been used in small series of selected patients. The technical aspects of catheter ablation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrophysiologic cardiac mapping techniques play an integral role during catheter ablation of ventricular arrhythmias. Mapping permits precise localization of the myocardial sites of origin of focal rhythm disturbances. These techniques and their application in localizing ventricular arrhythmias are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Use in specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation is employed for the management of ventricular arrhythmia in various clinical settings. It is generally recognized that ablation of VT in the setting of structural heart disease is more difficult than ablation of idiopathic VT. In patients with structural heart disease, adequate tissue ablation is often difficult to achieve due to the presence of relatively large reentrant circuits that they may be located deep in the myocardium. Moreover, many patients have multiple reentrant circuits, which further complicates the procedure.",
"   </p>",
"   <p>",
"    Catheter ablation is a \"stand-alone,\" potentially curative therapy for patients with idiopathic ventricular tachycardia (VT). In these patients, prognosis is excellent whether pharmacologic therapy or catheter ablation is undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with sustained monomorphic VT in the setting of structural heart disease, the cornerstone of therapy is generally the ICD. Adjunctive therapy with antiarrhythmic drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter ablation is usually offered to patients with recurrent ICD therapies for ventricular arrhythmia. In these patients, ablation may improve symptoms and quality of life but is rarely applied in the absence of an ICD. Some investigators have suggested that successful RF ablation may be adequate without ICD backup in patients with hemodynamically tolerated monomorphic VT due to a circumscribed area of scar with overall preserved left ventricular (LV) function, but this approach is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bundle branch reentrant VT may be cured with catheter ablation, but patients with this disorder have extensive structural heart disease, generally with poor LV function. Due to the risk of other ventricular arrhythmias, these patients generally receive ICDs, even if RF ablation for bundle branch reentrant VT is successful. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Bundle branch reentrant VT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SINGLE VPB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although isolated ventricular premature beats (VPB) are frequently encountered in clinical practice, they generally have no prognostic importance and are often asymptomatic or associated with only mild symptoms. However, there is a small group of patients with drug refractory VPBs who are very symptomatic. RF ablation may be an effective approach for these patients; in one study of 12 patients who did not have spontaneous or inducible sustained ventricular tachycardia (VT), RF ablation of an isolated focus was successful in 11 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/1\">",
"     1",
"    </a>",
"    ]. During a 25 month follow-up, two patients had recurrent symptoms that were controlled with a previously ineffective drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical significance and treatment of ventricular premature beats\", section on 'Radiofrequency ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports have suggested a possible link between frequent VPBs and nonischemic cardiomyopathy. In a report of 60 patients with idiopathic frequent VPBs, a reduced left ventricular ejection fraction was present in 22 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/2\">",
"     2",
"    </a>",
"    ]. Radiofrequency ablation was successful in 48 patients. Left ventricular function normalized in 18 of the 22 patients with reduced ejection fraction at baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rare cases, repetitive unifocal PVCs seem to induce ventricular fibrillation (VF). In small numbers of patients, successful ablation of these repetitive PVC's has led to resolution of VF storm. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ventricular fibrillation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     REENTRANT (SUSTAINED MONOMORPHIC) VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of reentrant ventricular tachycardias that have been treated with ablation are of the sustained monomorphic form, and many of the patients studied have had ischemic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Site of ablation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Endocardial catheter mapping and ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have reviewed the methods for locating the site of VT for ablation, generally from the endocardial surface [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. These include activation mapping, entrainment mapping, pace mapping, and substrate mapping. A nonfluoroscopic catheter-based electroanatomic mapping system, CARTO, has a magnetic field emitter and sensor and can create a replica of the anatomy of the cardiac chamber in which the tachycardia focus is located, permitting more precise localization of the arrhythmia focus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/10\">",
"     10",
"    </a>",
"    ]. NavX is another example of a nonfluoroscopic electroanatomic mapping system. Electroanatomic mapping images also allow identification of anatomic sites of interest around an arrhythmia focus. The CARTO system may be particularly useful for patients with unmappable VT. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Unmappable VT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Epicardial catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less commonly performed than endocardial ablation, epicardial ablation is possible both surgically and percutaneously via subxiphoid access of the pericardial space [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The feasibility of this approach was demonstrated in a report of 48 patients with a variety of arrhythmias (30 patients had ventricular tachycardia [VT], 10 had accessory pathways [APs], four had inappropriate sinus tachycardia [IST], and four had atrial fibrillation or atrial flutter) who had failed endocardial ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/11\">",
"     11",
"    </a>",
"    ]. In this series of patients, the majority of VTs and APs originated from the epicardium. Of these epicardial arrhythmias, 60 to 70 percent were safely and successfully mapped and ablated via a subxiphoid percutaneous approach. This approach was less useful in the small number of patients with IST, atrial fibrillation, or atrial flutter. No significant complications were reported in any of the patients.",
"   </p>",
"   <p>",
"    In some centers, epicardial ablation is used as a first-line ablation option for patients with ventricular tachyarrhythmias. In a study of 218 patients undergoing epicardial ablation at one of six high-volume VT ablation centers, 78 patients (36 percent) underwent epicardial ablation as their initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/14\">",
"     14",
"    </a>",
"    ]. Among all 218 patients who underwent epicardial ablation, 69 percent remained free of recurrent VT after a mean follow-up of 17 months. While there were no deaths attributed to the procedure, eight patients experienced cardiac tamponade, and one patient experienced an abdominal hemorrhage following epicardial ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unmappable VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, conventional EP mapping to localize the origin of the VT is difficult or impossible for one or more of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The arrhythmia is hemodynamically unstable. In such cases, the patient cannot be left in VT long enough for detailed mapping information to be collected using conventional methods.",
"     </li>",
"     <li>",
"      There are multiple VT morphologies.",
"     </li>",
"     <li>",
"      VT cannot be induced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When VT cannot be mapped by conventional methods, two general approaches may still allow VT ablation. First, for VT that is inducible but hemodynamically unstable, noncontact mapping technologies allow the identification of the arrhythmia site of origin and activation sequence from a single beat. Thus, an appropriate site of ablation can be identified without sustained VT. Noncontact mapping approaches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link&amp;anchor=H21#H21\">",
"     \"Electrophysiologic cardiac mapping: Techniques\", section on 'Noncontact mapping'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second approach to the catheter ablation of unmappable VT involves the identification of arrhythmic substrate (ie, myocardial scar), rather than the definitive site of arrhythmia origin. The arrhythmogenic substrate can be identified by such methods as abnormal systolic movement, the presence of fragmentation (prolonged electrograms with low amplitude), and pace mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the most common methods of substrate mapping, electroanatomic mapping using the CARTO or NavX system can accurately delineate scar tissue, which has lower voltage than normal myocardium. Areas of low voltage can be identified during sinus rhythm, allowing the identification of VT substrate without inducing or sustaining VT. Pace mapping of sites bordering the scar can identify appropriate sites for ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combinations of mapping techniques can improve ablation efficacy, particularly in patients with pleomorphic, unstable, or incessant VT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for a combination of approaches was provided in a study of 231 patients with recurrent monomorphic VT of which 69 percent of patients had unmappable VT. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'For recurrent VT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adjunct to ICD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     For recurrent VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial number of patients with an implantable cardioverter-defibrillator (ICD) require concomitant therapy with antiarrhythmic drugs to decrease the recurrence of clinical arrhythmia and the frequency of ICD shocks. An alternative approach is RF ablation as an adjunct to ICD therapy, which has been studied largely in patients with VT due to prior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/18,22-25\">",
"     18,22-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of this approach in patients with recurrent monomorphic VT caused by prior MI was illustrated by a report of 231 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with multiple VTs (median of 3 per patient) or unmappable VTs (present in 69 percent of patients) were included. All inducible monomorphic VTs with rates similar to or slower than any spontaneous VTs were targeted for irrigated RF ablation guided by electroanatomic mapping and other methods. Nearly all (94 percent) patients also had ICDs before ablation. The primary end point of freedom from recurrent VT at 6 months follow-up was achieved in 53 percent of patients. In 142 patients with ICDs who survived 6 months, VT episodes decreased from a median of 11.5 to zero. The procedure mortality rate was 3 percent, with no strokes. The one year mortality rate was 18 percent with 37.5 percent of deaths attributed to ventricular arrhythmias and 35 percent attributed to heart failure.",
"   </p>",
"   <p>",
"    Limited data are available on the efficacy of ablation to treat sustained VT following valve surgery. In one series, ablation was performed in 16 of 20 patients with sustained VT presenting 3 days to 16 years following aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral valve surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/26\">",
"     26",
"    </a>",
"    ]. VT was attributed to scar-related reentry in 14 patients and to bundle-branch reentry in two patients. Nine of the 14 patients with scar-related reentry had perivalvular scar. At a median follow-up of 2.1 years, 11 patients remained free of spontaneous VT.",
"   </p>",
"   <p>",
"    Cost-effectiveness for radiofrequency ablation relative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy was calculated in patients with an ICD with recurrent VT in an analysis using estimated event probabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/27\">",
"     27",
"    </a>",
"    ]. The five year costs were higher for ablation compared to amiodarone ($21,795 versus $19,075), but the quality of life was greater for ablation. The cost effectiveness ratio was $20,923 per quality-adjusted life-years gained for ablation compared to amiodarone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     For electrical storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical storm, also known as arrhythmic storm, refers to frequent recurrences of VT or VF (eg, three or more episodes during a 24 hour period). Among patients with an ICD, electrical storm may trigger repeated appropriate discharges (also known as defibrillator storm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H20#H20\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Electrical storm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of catheter ablation to treat drug-refractory electrical storm caused by recurrent VT in patients with an ICD was prospectively evaluated in a series of 95 patients with coronary artery disease (72 patients), idiopathic dilated cardiomyopathy (10 patients) or arrhythmogenic right ventricular cardiomyopathy (13 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/24\">",
"     24",
"    </a>",
"    ]. After one to three procedures, electrical storm was acutely suppressed in all patients and 85 patients had no inducible clinical VT. At a median follow-up of 22 months, 87 patients (92 percent) were free of electrical storm. Cardiac mortality was lower among patients in whom all clinical VTs were no longer inducible than in those who remained inducible (8 versus 40 percent). These findings suggest that early catheter ablation therapy may benefit patients with electrical storm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of ablation for treatment of VF storm is discussed separately. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ventricular fibrillation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prophylactic ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of prophylactic RF ablation of arrhythmogenic substrate as an adjunct to ICD therapy in patients with prior MI and a spontaneous ventricular arrhythmic event (but not multiple or incessant VT requiring immediate treatment) was evaluated in the SMASH-VT and VTACH trials.",
"   </p>",
"   <p>",
"    The SMASH-VT trial enrolled 128 subjects with an ICD placed either for secondary prevention (for VF or hemodynamically unstable VT or syncope with inducible VT) or for primary prevention with subsequent delivery of an appropriate ICD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/29\">",
"     29",
"    </a>",
"    ]. The study was conducted at two US and one European center. Patients were randomly assigned to either ICD alone or ICD with adjunctive RF ablation with substrate mapping. During the 23 month mean follow-up period, appropriate ICD therapy occurred more frequently in the ICD alone group and than in the ablation group (33 versus 12 percent of patients). Ablation had no significant effect on mortality (9 percent with ablation versus 17 percent for controls). Ablation-related complications occurred in three patients (pericardial tamponade, HF requiring prolonged hospitalization, and deep venous thrombosis) and there were no procedural deaths.",
"   </p>",
"   <p>",
"    In the VTACH trial, 110 subjects with stable VT, prior MI and LVEF &le;50 percent were randomly assigned to either catheter ablation plus an ICD or ICD alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/30\">",
"     30",
"    </a>",
"    ]. The study was conducted in 16 centers in four European countries. Time to VF or recurrent VT was longer in the ablation group than in the control group (median 18.6 versus 5.9 months). Estimated survival free from VT or VF at 2 years was higher in the ablation group than in the control group (47 versus 29 percent; HR 0.61; 95% CI 0.37-0.99). No significant difference in quality of life was found. Ablation-related complications occurred in two patients (one had transient ST elevation and one had a transient cerebral ischemic event) there were no procedural deaths.",
"   </p>",
"   <p>",
"    While the data from SMASH-VT and VTACH trials suggest that early ablation can be beneficial with low procedural risk, an impact on mortality or quality of life has not been demonstrated. Thus, the role of prophylactic RF ablation at the time of ICD implantation is not yet clear and is not routine practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BUNDLE BRANCH REENTRANT VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bundle branch reentrant VT (BBRVT) is a special form of sustained monomorphic VT involving abnormal conduction through normally present structures: the bundle of His and the bundle branches. It occurs with both ischemic and nonischemic heart disease, generally in the setting of LV dilatation with a left bundle branch block (LBBB) pattern during sinus rhythm. Several percent of inducible monomorphic VT is due to bundle branch reentry, but the arrhythmia may be difficult to induce. The site of ablation for VT due to bundle branch reentry is generally the right bundle branch, which is easily approached from the right heart [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Efficacy of ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation has been very successful in BBRVT due to bundle branch reentry that characteristically has a left (rarely a right) bundle branch morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Excellent success rates were noted in a study of ablation in 28 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/33\">",
"     33",
"    </a>",
"    ]. These results suggest that ablation therapy is the treatment of choice for this type of VT; current practice generally includes ICD implantation as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IDIOPATHIC VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;VT not associated with structural organic heart disease usually arises in the right ventricular outflow tract (also called repetitive monomorphic VT). These arrhythmias most commonly have an electrocardiographic pattern of left bundle branch block with right axis deviation, presumably arising from the right ventricular outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/35\">",
"     35",
"    </a>",
"    ]. Less commonly, idiopathic VT presents with a right bundle branch block pattern with a leftward axis, presumably arising from the inferoapical region of the left ventricular side of the septum, near the posterior fascicle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/36\">",
"     36",
"    </a>",
"    ]. Idiopathic VT may also arise from the left ventricular outflow tract, aortic cusps, or anterior interventricular septum, resulting in an inferior axis VT with variable V1 morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic VT may also arise from the tricuspid annulus; such arrhythmias are probably not as rare as previously thought and are susceptible to radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/39\">",
"     39",
"    </a>",
"    ]. The QRS complexes have a LBBB pattern, an R or r pattern in lead I, and usually a negative initial component in aVR. VT arising from the free wall portion of the annulus had a longer QRS duration than VT arising from the septal portion, and \"notching\" of the mid or late component of the QRS was seen more frequently in the VT arising from the free wall portion. A Q in V1 was observed more often if the arrhythmia arose from the septal portion of the tricuspid annulus.",
"   </p>",
"   <p>",
"    Idiopathic VT arising from either the right or left ventricle (called right and left ventricular tachycardia, respectively) can be precipitated by catecholamines or exercise, and terminated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or adenosine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Site of ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic right ventricular tachycardia probably results from a mechanism other than reentry, most likely being triggered by activity from a very localized area of myocardium. Pace mapping is a useful means to identify the best sites for ablations in idiopathic VT arising from the right ventricular outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for idiopathic left ventricular tachycardia is probably reentry, originating in the posterior Purkinje fiber network located in the apicoseptal portion of the left ventricle or midinferior septum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/40\">",
"     40",
"    </a>",
"    ]. The target for ablation in idiopathic left ventricular tachycardia is often best defined as site with the earliest local electrogram and identification of an abnormal retrograde Purkinje potential [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/36,40,41\">",
"     36,40,41",
"    </a>",
"    ]. Risks of complications, particularly involving the coronary arteries, are higher with left ventricular forms than with right ventricular tachycardia.",
"   </p>",
"   <p>",
"    Intracardiac echocardiography (ICE) with 2D and Doppler color flow imaging may be useful to guide mapping and ablation catheters and monitor morphologic changes after ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Efficacy of ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of ablation studies of modest size have now been reported in idiopathic VT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/35,36,41,43-49\">",
"     35,36,41,43-49",
"    </a>",
"    ]. Initial success rates range from 75 to 100 percent for tachycardias that originate in the right ventricular outflow tract, and 50 to 90 percent for those that originate at other sites. In addition, success may be lower when the site of origin is not endocardial and not definitively identified during mapping. One study of 75 patients found that the inability to identify a focus, and hence the success rate, correlated with the QRS duration; the success rate was 95 percent when the QRS complex in V2 during pacing mapping was &ge;160 ms in duration, while the success rate was only 54 percent if the QRS duration was &lt;160 ms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited information on long-term follow-up. In one study of 20 patients with idiopathic left ventricular tachycardia, the initial success rate was 85 percent and there were no recurrences at 7 &plusmn; 8 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/49\">",
"     49",
"    </a>",
"    ]. Six patients underwent a repeat electrophysiologic study; none were inducible. A second study of 13 patients with right ventricular outflow tract VT reported that all tachycardias were successfully ablated; during a 28 month follow-up only one patient had a recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another review of 13 patients with idiopathic left ventricular tachycardia reported success in 92 percent; among 35 patients with idiopathic right ventricular outflow tract VT, 14 percent had a recurrence after a follow-up of 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/52\">",
"     52",
"    </a>",
"    ]. A good pacemap was more important than the earliest local endocardial electrogram in those with right ventricular VT, while both an optimal pacemap and the earliest endocardial electrogram were important for successful ablation of left ventricular VT. Factors predictive of unsuccessful ablation were greater than one induced VT morphology, a delta wave-like beginning of the QRS, and a match between the clinical VT and pacemap in less than 11 of 12 leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER FORMS OF VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ablation in arrhythmogenic right ventricular",
"    <span class=\"nowrap\">",
"     cardiomyopathy/dysplasia",
"    </span>",
"    and tetralogy of Fallot remains to be defined. Preliminary evidence suggests that RF ablation may be successful in some patients with sustained VT and dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/53\">",
"     53",
"    </a>",
"    ]. RF ablation in all of these settings has been primarily used in patients with an ICD who have had recurrent shocks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"     \"Overview of the management of tetralogy of Fallot\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     VENTRICULAR FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare patients with VF (including some with VF storm) or polymorphic VT, unifocal PVCs seem to trigger or induce the episodes of ventricular arrhythmia. Several small series suggest that these PVCs may emanate from the Purkinje system or right ventricular outflow tract, and that successful ablation of these PVCs resolves the ventricular arrhythmia. This has been reported in patients with ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/54\">",
"     54",
"    </a>",
"    ], amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/55\">",
"     55",
"    </a>",
"    ], and structurally normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], including patients with long QT and Brugada syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H11#H11\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Idiopathic VF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H26#H26\">",
"     \"Prognosis and management of congenital long QT syndrome\", section on 'Radiofrequency ablation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for catheter ablation of ventricular arrhythmias were included in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death (",
"    <a class=\"graphic graphic_table graphicRef67056 \" href=\"UTD.htm?28/8/28812\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree generally with following more extensive recommendations included in the 2009 European Heart Rhythm",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (EHRA/HRS)",
"    </span>",
"    expert consensus on catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with structural heart disease (such as prior MI, dilated cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy) catheter ablation is recommended for any of the following conditions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptomatic sustained monomorphic VT (SMVT) including VT terminated by an ICD, that recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or not desired",
"     </li>",
"     <li>",
"      Incessant SMVT or VT storm not due to a transient reversible cause",
"     </li>",
"     <li>",
"      Frequent PVCs, non-sustained VTs or VT that is presumed to cause ventricular dysfunction",
"     </li>",
"     <li>",
"      Bundle branch reentrant or interfascicular VTs",
"     </li>",
"     <li>",
"      Recurrent SMVT and VF that is refractory to antiarrhythmic therapy when there is a suspected trigger that can be targeted for ablation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with structural heart disease, catheter ablation should be considered for patients with any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One or more episodes of SMVT despite therapy with one or more Class I or III antiarrhythmic drugs",
"     </li>",
"     <li>",
"      Recurrent SMVT due to prior MI with LVEF &gt;30 percent and expectation for at least one year of survival as an acceptable alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy",
"     </li>",
"     <li>",
"      Hemodynamically tolerated SMVT due to prior MI who have reasonably preserved LVEF (&gt;35 percent) even if they have not failed antiarrhythmic drug therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without structural heart disease catheter ablation is recommended for patients with idiopathic VT for",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severely symptomatic monomorphic VT",
"     </li>",
"     <li>",
"      Monomorphic VT when antiarrhythmic drugs are not effective, not tolerated or not desired.",
"     </li>",
"     <li>",
"      Recurrent sustained polymorphic VT and VF (electrical storm) that is refractory to antiarrhythmic therapy when there is a suspected trigger that can be targeted for ablation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Catheter ablation of VT is contraindicated in the presence of a mobile ventricular thrombus (epicardial ablation may be considered), for asymptomatic PVCs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NSVT that are not suspected of causing or contributing to ventricular dysfunction, for VT due to transient, reversible causes, such as acute ischemia, hyperkalemia, or drug-induced torsade de pointes.",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"       \"Patient information: Radiofrequency catheter ablation for the heart (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"       \"Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation for the treatment of VT has been variably successful depending upon the type and etiology of the arrhythmia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheter ablation has been highly successful in the following settings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Idiopathic VT: For patients without structural heart disease with symptomatic VT we recommend catheter ablation as an alternative to long-term pharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Idiopathic VT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bundle branch reentrant VT: For patients with bundle branch reentrant VT, we recommend catheter ablation. However, due to the severity of underlying cardiac disease, patients with BBRVT remain at high risk for other ventricular arrhythmias and many meet general indications for ICD therapy for the primary prevention of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13129/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H26#H26\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H26#H26\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Bundle branch reentrant VT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"       \"Bundle branch reentrant ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheter ablation has been moderately successful in the treatment of reentrant tachycardias, particularly in the presence of coronary disease and prior MI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with structural heart disease with SMVT, catheter ablation is recommended as adjunctive therapy in patients with an ICD who have frequent episodes of VT and ICD shocks. Because the risk of potentially fatal VT is relatively high, catheter ablation is considered an adjunct to rather than an alternative to ICD therapy in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/1\">",
"      Lauribe P, Shah D, Ja&iuml;s P, et al. Radiofrequency catheter ablation of drug refractory symptomatic ventricular ectopy: short- and long-term results. Pacing Clin Electrophysiol 1999; 22:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/2\">",
"      Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007; 4:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/3\">",
"      Kim YH, O'Nunain S, Ruskin JN, Garan H. Nonpharmacologic therapies in patients with ventricular tachyarrhythmias. Catheter ablation and ventricular tachycardia surgery. Cardiol Clin 1993; 11:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/4\">",
"      Blanck Z, Dhala A, Deshpande S, et al. Catheter ablation of ventricular tachycardia. Am Heart J 1994; 127:1126.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Supraventricular tachycardias. In: Clincal Cardiac Electrophysiology: Techniques and Interpretations, 4th, Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.262.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/6\">",
"      D'Avila A, Nellens P, Andries E, Brugada P. Catheter ablation of ventricular tachycardia occurring late after myocardial infarction: a point-of-view. Pacing Clin Electrophysiol 1994; 17:532.",
"     </a>",
"    </li>",
"    <li>",
"     Prystowsky EN, Klein GJ. Cardiac Arrhythmias: An Integrated Approach for the Clinician, McGraw-Hill, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/8\">",
"      Delacretaz E, Stevenson WG. Catheter ablation of ventricular tachycardia in patients with coronary heart disease: part I: Mapping. Pacing Clin Electrophysiol 2001; 24:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/9\">",
"      Bogun F, Good E, Reich S, et al. Isolated potentials during sinus rhythm and pace-mapping within scars as guides for ablation of post-infarction ventricular tachycardia. J Am Coll Cardiol 2006; 47:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/10\">",
"      Nademanee K, Kosar EM. A nonfluoroscopic catheter-based mapping technique to ablate focal ventricular tachycardia. Pacing Clin Electrophysiol 1998; 21:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/11\">",
"      Schweikert RA, Saliba WI, Tomassoni G, et al. Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation 2003; 108:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/12\">",
"      Sosa E, Scanavacca M. Epicardial mapping and ablation techniques to control ventricular tachycardia. J Cardiovasc Electrophysiol 2005; 16:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/13\">",
"      Valderr&aacute;bano M, Cesario DA, Ji S, et al. Percutaneous epicardial mapping during ablation of difficult accessory pathways as an alternative to cardiac surgery. Heart Rhythm 2004; 1:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/14\">",
"      Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol 2011; 4:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/15\">",
"      Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation 2001; 104:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/16\">",
"      Furniss S, Anil-Kumar R, Bourke JP, et al. Radiofrequency ablation of haemodynamically unstable ventricular tachycardia after myocardial infarction. Heart 2000; 84:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/17\">",
"      Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000; 101:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/18\">",
"      Sra J, Bhatia A, Dhala A, et al. Electroanatomically guided catheter ablation of ventricular tachycardias causing multiple defibrillator shocks. Pacing Clin Electrophysiol 2001; 24:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/19\">",
"      Arenal A, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with an isolated, delayed component as treatment of unmappable monomorphic ventricular tachycardias in patients with structural heart disease. J Am Coll Cardiol 2003; 41:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/20\">",
"      Kottkamp H, Wetzel U, Schirdewahn P, et al. Catheter ablation of ventricular tachycardia in remote myocardial infarction: substrate description guiding placement of individual linear lesions targeting noninducibility. J Cardiovasc Electrophysiol 2003; 14:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/21\">",
"      Klemm HU, Ventura R, Steven D, et al. Catheter ablation of multiple ventricular tachycardias after myocardial infarction guided by combined contact and noncontact mapping. Circulation 2007; 115:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/22\">",
"      Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 1997; 96:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/23\">",
"      O'Callaghan PA, Poloniecki J, Sosa-Suarez G, et al. Long-term clinical outcome of patients with prior myocardial infarction after palliative radiofrequency catheter ablation for frequent ventricular tachycardia. Am J Cardiol 2001; 87:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/24\">",
"      Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/25\">",
"      Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008; 118:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/26\">",
"      Eckart RE, Hruczkowski TW, Tedrow UB, et al. Sustained ventricular tachycardia associated with corrective valve surgery. Circulation 2007; 116:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/27\">",
"      Calkins H, Bigger JT Jr, Ackerman SJ, et al. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. Circulation 2000; 101:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/28\">",
"      Sapp JL. Venturing into the storm. Circulation 2008; 117:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/29\">",
"      Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/30\">",
"      Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010; 375:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/31\">",
"      Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988; 78:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/32\">",
"      Caceres J, Jazayeri M, McKinnie J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989; 79:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/33\">",
"      Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993; 4:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/34\">",
"      Cohen TJ, Chien WW, Lurie KG, et al. Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: results and long-term follow-up. J Am Coll Cardiol 1991; 18:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/35\">",
"      Wilber DJ, Baerman J, Olshansky B, et al. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation 1993; 87:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/36\">",
"      Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 1993; 88:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/37\">",
"      Callans DJ, Menz V, Schwartzman D, et al. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997; 29:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/38\">",
"      Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 2002; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/39\">",
"      Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias originating from the tricuspid annulus: Prevalence, electrocardiographic characteristics, and results of radiofrequency catheter ablation. Heart Rhythm 2007; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/40\">",
"      Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the purkinje network. Circulation 2002; 105:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/41\">",
"      Klein LS, Miles WM, Hackett FK, Zipes DP. Catheter ablation of ventricular tachycardia using radiofrequency techniques in patients without structural heart disease. Herz 1992; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/42\">",
"      Ren JF, Marchlinski FE. Utility of intracardiac echocardiography in left heart ablation for tachyarrhythmias. Echocardiography 2007; 24:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/43\">",
"      Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/44\">",
"      Stevenson WG, Nademanee K, Weiss JN, Wiener I. Treatment of catecholamine-sensitive right ventricular tachycardia by endocardial catheter ablation. J Am Coll Cardiol 1990; 16:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/45\">",
"      Morady F, Kadish AH, DiCarlo L, et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation 1990; 82:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/46\">",
"      Calkins H, Kalbfleisch SJ, el-Atassi R, et al. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 1993; 71:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/47\">",
"      Page RL, Shenasa H, Evans JJ, et al. Radiofrequency catheter ablation of idiopathic recurrent ventricular tachycardia with right bundle branch block, left axis morphology. Pacing Clin Electrophysiol 1993; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/48\">",
"      Wellens HJ, Smeets JL. Idiopathic left ventricular tachycardia. Cure by radiofrequency ablation. Circulation 1993; 88:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/49\">",
"      Wen MS, Yeh SJ, Wang CC, et al. Radiofrequency ablation therapy in idiopathic left ventricular tachycardia with no obvious structural heart disease. Circulation 1994; 89:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/50\">",
"      Flemming MA, Oral H, Kim MH, et al. Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract. Am J Cardiol 1999; 84:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/51\">",
"      Chinushi M, Aizawa Y, Takahashi K, et al. Radiofrequency catheter ablation for idiopathic right ventricular tachycardia with special reference to morphological variation and long-term outcome. Heart 1997; 78:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/52\">",
"      Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. Predictors for successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol 1997; 79:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/53\">",
"      Kottkamp H, Hindricks G, Chen X, et al. Radiofrequency catheter ablation of sustained ventricular tachycardia in idiopathic dilated cardiomyopathy. Circulation 1995; 92:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/54\">",
"      Marrouche NF, Verma A, Wazni O, et al. Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2004; 43:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/55\">",
"      Mlcochova H, Saliba WI, Burkhardt DJ, et al. Catheter ablation of ventricular fibrillation storm in patients with infiltrative amyloidosis of the heart. J Cardiovasc Electrophysiol 2006; 17:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/56\">",
"      Ha&iuml;ssaguerre M, Shoda M, Ja&iuml;s P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002; 106:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/57\">",
"      Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol 2005; 46:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/58\">",
"      Ha&iuml;ssaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003; 108:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/59\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/60\">",
"      Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace 2009; 11:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13129/abstract/61\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 919 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13129=[""].join("\n");
var outline_f12_52_13129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL UTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SINGLE VPB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      REENTRANT (SUSTAINED MONOMORPHIC) VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Site of ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Endocardial catheter mapping and ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Epicardial catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unmappable VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adjunct to ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - For recurrent VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - For electrical storm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prophylactic ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BUNDLE BRANCH REENTRANT VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Efficacy of ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IDIOPATHIC VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Site of ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Efficacy of ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER FORMS OF VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      VENTRICULAR FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/919|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/8/28812\" title=\"table 1\">",
"      ACC AHA ablation ventric tachy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=related_link\">",
"      Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13130="Erythema nodosum";
var content_f12_52_13130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythema nodosum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Kaveh G Shojania, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/52/13130/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/52/13130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema nodosum (EN) is characterized by red or violet subcutaneous nodules that usually develop in a pretibial location. EN is presumed to represent a delayed hypersensitivity reaction to antigens associated with the various infectious agents, drugs, and other diseases with which it is associated, although the pathogenesis is largely unclear. EN occurs in a variety of disorders for which the etiology remains unknown; for example, sarcoidosis, inflammatory bowel disease, and Beh&ccedil;et&rsquo;s disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of EN is approximately 1 to",
"    <span class=\"nowrap\">",
"     5/100,000",
"    </span>",
"    persons, most often women ages 15 to 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with EN have evidence of recent streptococcal infection or have no identifiable cause; in such cases, symptomatic relief constitutes the only treatment necessary. However, in 15 to 40 percent of cases, EN represents an early sign of a variety of infections, connective tissue diseases, and other inflammatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/1-3,6\">",
"     1-3,6",
"    </a>",
"    ]. The frequency with which different diseases that have been associated with EN are found varies with the population studied (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Causes of erythema nodosum'",
"    </a>",
"    below.) Thus, careful diagnostic assessment constitutes the most important aspect of management for patients presenting with EN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of cases, painful, erythematous nodules develop on the anterior surfaces of both legs, and evolve into bruise-like lesions that resolve without scarring over a two- to eight-week period (",
"    <a class=\"graphic graphic_picture graphicRef80056 \" href=\"UTD.htm?8/46/8943\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/2,3,6-9\">",
"     2,3,6-9",
"    </a>",
"    ]. The lesions are deep nodules that may be more easily palpated than visualized. Lesions can also appear on the thighs, trunk, and upper extremities, but absence of nodules on the legs is atypical.",
"   </p>",
"   <p>",
"    Polyarthralgia, fever, and malaise frequently accompany EN (sometimes in advance of skin findings). The erythrocyte sedimentation rate is often elevated, but remains normal in 15 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/2,3,5,10\">",
"     2,3,5,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, EN is a panniculitis involving inflammation of septa in the subcutaneous fat tissue, usually without associated vasculitis, although small vessel inflammatory changes occasionally occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Typical septal inflammation with lobular sparing is shown in the picture (",
"    <a class=\"graphic graphic_picture graphicRef80108 \" href=\"UTD.htm?31/46/32484\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of this disorder is most often clinical, with biopsy required only in atypical cases (eg, patients with no lesions on the legs, persistence beyond six to eight weeks, or the development of ulceration). In areas where tuberculosis is endemic, biopsy may be warranted since the organism can be identified in the biopsy material [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. When biopsy is obtained, it is crucial to obtain a deep incisional biopsy; punch biopsy frequently produces samples inadequate for pathologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following diagnostic testing is recommended to help establish a probable cause or the presence of an associated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Causes of erythema nodosum'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and differential",
"     </li>",
"     <li>",
"      Liver enzyme (aminotransferases, alkaline phosphatase), bilirubin, albumin",
"     </li>",
"     <li>",
"      Serum creatinine and urea nitrogen",
"     </li>",
"     <li>",
"      Antistreptolysin-O titer at diagnosis and two to four weeks later to assess for antecedent streptococcal infection.",
"     </li>",
"     <li>",
"      Plain chest radiograph to assess for hilar adenopathy or other evidence of pulmonary sarcoidosis, tuberculosis, or fungal infection.",
"     </li>",
"     <li>",
"      Skin testing for tuberculosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous eruptions that can be confused with EN include other forms of panniculitis, especially nodular vasculitis (also called erythema induratum), subcutaneous infections due to bacteria or fungi, superficial thrombophlebitis, and cutaneous vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/12,18-22\">",
"     12,18-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=see_link\">",
"     \"Panniculitis: Recognition and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Nodular vasculitis (erythema induratum)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular vasculitis, also called erythema induratum and Bazin disease, is the primary alternative diagnosis in patients with inflammatory nodules of less than eight weeks' duration involving the legs. Some case series report clinical distinctions between nodular vasculitis and EN, with the former more commonly involving the posterior aspects of the legs, and more prone to ulceration and recurrence than EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/9,23,24\">",
"     9,23,24",
"    </a>",
"    ]. Other series, however, have indicated considerable overlap between the clinical appearances of these entities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/25\">",
"     25",
"    </a>",
"    ]. Primary tuberculosis is a leading cause of nodular vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remaining entities in the differential diagnosis of EN-like eruptions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Superficial thrombophlebitis",
"     </li>",
"     <li>",
"      Cutaneous vasculitides",
"     </li>",
"     <li>",
"      Subcutaneous infections with typical bacteria such as staphylococci, and less commonly infectious agents that produce nodular lymphangitis (eg, Sporothrix schenckii, Nocardia brasiliensis, Mycobacterium marinum, Leishmania braziliensis, and Francisella tularensis) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/20,26\">",
"       20,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subcutaneous granuloma annulare [",
"      <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical confusion between EN and these disorders occurs in only a minority of cases. Thus, in areas where tuberculosis is not endemic, biopsy can be reserved for atypical cases as mentioned above (eg, patients with no lesions on the legs, persistence beyond six to eight weeks, or the development of ulceration).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CAUSES OF ERYTHEMA NODOSUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table lists the diagnoses attributed to patients with EN in case series from around the world over the past 50 years (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/1-3,5,6,10,27,28\">",
"     1-3,5,6,10,27,28",
"    </a>",
"    ]. Other studies were omitted on the basis of outdated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/8,29\">",
"     8,29",
"    </a>",
"    ] or unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] diagnostic categories, and diagnostic protocols that remained unspecified or appeared too focused upon identifying specific diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. These studies do provide valuable information regarding the features of specific conditions associated with EN, and are cited in those sections.",
"   </p>",
"   <p>",
"    As previously mentioned, cases occurring in the setting of recent streptococcal infection or in the absence of an identifiable cause account for the majority of patients in all case series. In Europe and North America, sarcoidosis constitutes a dominant cause of EN, while tuberculosis remains an important underlying condition in other parts of the world. Thus, studies that may be helpful in excluding these diseases include antistreptolysin O (ASO) titer, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    , and a chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/17\">",
"     17",
"    </a>",
"    ]. Pregnancy and oral contraceptive use explain a minority of cases, while inflammatory bowel disease, Hodgkin lymphoma, and Beh&ccedil;et&rsquo;s disease each appear in at least one case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dominant causes of EN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Streptococcal pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal pharyngitis probably represents the single most frequent condition associated with EN worldwide; however, as one study suggests [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/5\">",
"     5",
"    </a>",
"    ], stricter diagnostic criteria may reveal many of these cases to be other upper respiratory tract infections. Cases attributed to Streptococcal pharyngitis include a mixture of \"definite\" cases (culture proven or change in antistreptolysin (ASO) antibody titer) and \"probable\" cases; the former account for at least one-half of cases (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). Many of the patients in these studies exhibited serological evidence of recent streptococcal infection in the absence of recent symptoms of pharyngitis. Thus, the evaluation of any patient with EN should include a throat culture and ASO titer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic cases account for 16 to 72 percent EN cases (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). Idiopathic EN is a diagnosis of exclusion; most of the other diagnoses associated with EN are suspected after the initial history and physical examination, and detected with appropriate investigations including chest x-ray, streptococcal throat culture and serology, as well as a skin biopsy in atypical cases. However, clinical follow-up is required to rule out conditions such as inflammatory bowel disease, primary tuberculosis, lymphoma, and Beh&ccedil;et&rsquo;s disease; EN may precede other manifestations of these diseases by months to years.",
"   </p>",
"   <p>",
"    The majority of other important conditions associated with EN can be considered in terms of two diagnostic patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EN associated with hilar adenopathy",
"     </li>",
"     <li>",
"      EN accompanied by gastrointestinal symptomatology",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Erythema nodosum with hilar adenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disorders may present with EN and hilar adenopathy (",
"    <a class=\"graphic graphic_table graphicRef53745 \" href=\"UTD.htm?3/27/3515\">",
"     table 2",
"    </a>",
"    ). Sarcoidosis is the classic disorder in this category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of sarcoidosis among patients with EN varies geographically (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). Among patients of Northern European decent, EN commonly occurs at presentation and confers a generally favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In contrast, EN is a less common feature of sarcoidosis in patients from other ethnic backgrounds (compared with direct sarcoid infiltration of the skin) and does not portend a favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/32,34-39\">",
"     32,34-39",
"    </a>",
"    ]. The series from Thailand and Singapore reported no cases of sarcoidosis, and the Israeli series included only one case of EN attributable to sarcoid.",
"   </p>",
"   <p>",
"    Lofgren's syndrome is defined as the triad of hilar adenopathy, acute polyarthritis, and EN. Patients with EN tend to be women, possess the HLA-DR3 allele, and have involvement of multiple joints [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/40\">",
"     40",
"    </a>",
"    ]. Lofgren's syndrome is usually a self-limited disorder; the EN typically disappears within weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of arthritis in a patient with EN and hilar adenopathy does not assure the diagnosis of sarcoidosis. As discussed below, histoplasmosis, coccidioidomycosis, yersiniosis, and Chlamydophila (formerly Chlamydia) pneumoniae can all produce this constellation of findings. The differential diagnosis in such cases must be narrowed largely on geographic and epidemiological grounds as well as laboratory testing. The presence of bilateral ankle arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] or uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/44,45\">",
"     44,45",
"    </a>",
"    ] strongly suggests the diagnosis of sarcoidosis in patients with EN and hilar adenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) formerly constituted the most important cause of EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/8,29,46\">",
"     8,29,46",
"    </a>",
"    ]. Currently, the prevalence of TB among patients presenting with EN has decreased markedly; nevertheless, more recent case series from Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/2\">",
"     2",
"    </a>",
"    ], Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/10\">",
"     10",
"    </a>",
"    ], France [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/3\">",
"     3",
"    </a>",
"    ], Greece [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/27\">",
"     27",
"    </a>",
"    ], Spain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/5\">",
"     5",
"    </a>",
"    ], and Singapore [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/28\">",
"     28",
"    </a>",
"    ] all reported at least one case. (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hilar adenopathy due to TB occurs in the setting of primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]; primary infection accounts for the majority of cases of EN associated with TB [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/1,6,8,29,47\">",
"     1,6,8,29,47",
"    </a>",
"    ]. Patients may present with a normal chest x-ray, and non-reactive tuberculin skin reactions. Thus, those at risk for TB exposure should be followed for several months to identify radiographic signs of TB or skin test conversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Coccidioidomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis occurs in arid regions of the United States, as well as Mexico and Central and South America. EN occurs in approximately 5 percent of all persons infected with coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/48\">",
"     48",
"    </a>",
"    ]; the prevalence increases to 15 to 40 percent in patients with acute, symptomatic presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Acute coccidioidomycosis frequently causes arthralgias or arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/50\">",
"     50",
"    </a>",
"    ], and may even complete the triad of Lofgren's syndrome with associated EN and bilateral hilar adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .) Similar to sarcoidosis, EN occurs more commonly in Caucasians with coccidioidomycoses compared with other ethnic groups, and represents an independent predictor of a more favorable prognosis in terms of the risks of chronic or disseminated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/50,52\">",
"     50,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During a massive outbreak of histoplasmosis in Indiana from 1978 to 1979, 18 out of 435 laboratory-confirmed cases (4.1 percent) presented with EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/53\">",
"     53",
"    </a>",
"    ]. In two earlier histoplasmosis outbreaks, erythema multiforme occurred more commonly than EN, but the two eruptions frequently occurred together [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. EN usually occurred in the first or second week of illness, although skin lesions preceded pulmonary complaints by one to two weeks in a significant minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/55\">",
"     55",
"    </a>",
"    ]. Acute histoplasmosis can mimic Lofgren's syndrome by presenting with the triad of EN, hilar adenopathy, and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;One patient from the Scottish series in the table presented with mediastinal adenopathy atypical for sarcoidosis and eventually proved to have Hodgkin lymphoma (HL) (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). Two case series from the non-English language literature mention single cases of EN due to non-Hodgkin lymphoma (NHL) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Other reports of the association with HL or NHL describe a history of recurrent or persistent EN by the time the diagnosis became apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. Thus, while idiopathic EN may recur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], persistent or recurrent EN-like eruptions should prompt consideration of HL or NHL, and possibly T-cell lymphoma with direct skin infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/25,64\">",
"     25,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Chlamydophila infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first association between EN and chlamydophila infection involved psittacosis, but the English language literature describes only a handful of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Other chlamydophila infections subsequently emerged as causes of EN, particularly Chlamydophila pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. All eleven patients in one of these reports described respiratory complaints at the time of presentation with EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/69\">",
"     69",
"    </a>",
"    ]. A more recent series, however, describes three of seven consecutive patients with the presumptive diagnosis of Lofgren's syndrome (due to sarcoidosis) who proved to have C. pneumoniae as the underlying diagnosis on the basis of serological studies and response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/72\">",
"     72",
"    </a>",
"    ]. The case series from France (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ) and two other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/69,73\">",
"     69,73",
"    </a>",
"    ] describe cases of EN attributable to infection with C. trachomatis; lymphogranuloma venereum also has rarely been reported as a cause of EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Yersiniosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yersiniosis was first identified as a cause of EN in 1970 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/76\">",
"     76",
"    </a>",
"    ]. It may represent a relatively common cause of EN in Northern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/4,77\">",
"     4,77",
"    </a>",
"    ]. Only one patient from all of the case series in the table received this diagnosis, and Yersinia is probably a rare cause of EN in North America (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/78\">",
"     78",
"    </a>",
"    ]. Interestingly, Yersinia can present with hilar adenopathy and EN in the absence of gastrointestinal complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Blastomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention was drawn to blastomycosis as a cause of EN after an outbreak of blastomycosis in the 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/80\">",
"     80",
"    </a>",
"    ]; more recent cases also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/81\">",
"     81",
"    </a>",
"    ]. In all of these patients, EN developed after pulmonary symptoms or findings, so the placement of blastomycosis under the differential diagnosis of unexplained EN and hilar adenopathy is questionable except in so far as the other mycoses also appear in this category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Erythema nodosum accompanied by gastrointestinal complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disorders may present with EN in combination with gastrointestinal complaints (",
"    <a class=\"graphic graphic_table graphicRef78442 \" href=\"UTD.htm?1/44/1739\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;EN is the most frequent cutaneous finding in patients with inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. At least one case of IBD appeared in four of the case series in the table (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/2,3,6,17\">",
"     2,3,6,17",
"    </a>",
"    ] and in two other case series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/4,31\">",
"     4,31",
"    </a>",
"    ]. EN occurs more commonly with Crohn's disease than with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of EN has a number of IBD-related associations, such as increased risks of other extraintestinal manifestations of IBD (eg, eye involvement, arthritis, and pyoderma gangrenosum), but observations regarding the relationship of EN to the severity of IBD have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. In one case series penetrating gastrointestinal complications were more frequent in patients who had developed EN, but in another series EN did not correlate with disease severity.",
"   </p>",
"   <p>",
"    Three of the patients in the table (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ) presented with histories of previous EN at least one year prior to developing gastrointestinal symptomatology. Typically, however, EN develops around the time of gastrointestinal flares, in contrast to pyoderma gangrenosum, which commonly runs a course independent of gastrointestinal disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment directed at the underlying bowel disease usually results in the elimination of EN. Systemic glucocorticoids may be necessary in the presence of refractory lesions that either precede bowel symptoms or that occur during quiescent phases of IBD, but their use requires a firmly established diagnosis of EN due to IBD.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     Potassium iodide",
"    </a>",
"    has also been reported effective for refractory EN due to IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Behcet's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease (BD) can cause identical mucocutaneous and gastrointestinal findings as Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/88-90\">",
"     88-90",
"    </a>",
"    ], as well as an increased risk of thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .) Four of the case series in the table reported more than one patient with BD as the cause of EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/10,17,27,28\">",
"     10,17,27,28",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). The three patients from the Thai series had no previous gastrointestinal history, but developed orogenital ulcers concurrent with EN-like skin lesions. The series from Greece, Spain, and Singapore contained no clinical details regarding the two patients with BD. A clinical series of 41 patients with BD reported EN in 32 percent of cases, but did not indicate how many patients presented with EN in the absence of symptoms or signs suggestive of BD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/92\">",
"     92",
"    </a>",
"    ]. A series of 137 cases of BD from Italy noted a prevalence of EN of 10 percent at the time of presentation and 40 percent at some point in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/93\">",
"     93",
"    </a>",
"    ]. Interestingly, another study found that 5 of 18 patients with BD presented with EN months to years in advance of ocular-oro-genital ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BD may be triggered by exposure to an infectious agent such as streptococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28874?source=see_link\">",
"     \"Pathogenesis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .) Thus, it is possible that patients acquire EN due to recent streptococcal infection and subsequently develop BD on the same basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Bacterial gastroenteritides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous reports document EN in association with bacterial gastroenteritides, including Salmonella species [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/96-101\">",
"     96-101",
"    </a>",
"    ] (as well as typhoidal vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/102\">",
"     102",
"    </a>",
"    ]), Campylobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/97,103,104\">",
"     97,103,104",
"    </a>",
"    ], and Shigella [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Yersiniosis accounted for a substantial proportion of cases in several series' from Northern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/4,77,107\">",
"     4,77,107",
"    </a>",
"    ], but provided the diagnosis for only one patient in the case series in the table (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). Patients with EN due to Yersinia can present with or without diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/76,79\">",
"     76,79",
"    </a>",
"    ], but in all cases establishing the diagnosis requires serological testing for Yersinia antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/76,77,79\">",
"     76,77,79",
"    </a>",
"    ] since stool cultures are negative even in symptomatic patients. EN due to Yersinia does not appear to require antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/3,76,79\">",
"     3,76,79",
"    </a>",
"    ], even when accompanied by gastrointestinal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    .) The purpose of establishing this diagnosis (or any of the other bacterial gastroenteritides) lies in reducing the concern for IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis is an uncommon cause of panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/9,19\">",
"     9,19",
"    </a>",
"    ] and only rarely produces a clinical picture resembling EN. One patient from the case series in the table apparently had pancreatitis, but no details are provided (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). The majority of case reports in the literature describe patients with EN-like lesions at the time of presentation with obvious pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/108,109\">",
"     108,109",
"    </a>",
"    ], or days to weeks into an established course of pancreatitis. One report, however, describes a patient who developed EN-like lesions two weeks prior to presentation with pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Whipple's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whipple's disease was omitted from the table, due to its rarity, but one report describes a patient with biopsy-proven Whipple's disease who presented with subcutaneous nodules resembling EN in the setting of chronic (unexplained) gastrointestinal complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other conditions associated with EN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other conditions may be associated with EN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Pregnancy and oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and oral contraceptives (OCs) are often cited as causes of EN; three of the series in the table reported at least one case (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). The concentration of cases of EN among women of reproductive age raises the possibility of coincident associations. However, the temporal associations in several reports, including recurrence of EN with subsequent pregnancies or resumption of OCs, and more recently hormone replacement therapy (HRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/112-117\">",
"     112-117",
"    </a>",
"    ], argue for a causal relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are often cited as causes of EN (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/2,10,17\">",
"     2,10,17",
"    </a>",
"    ]. Ruling out coincidence is often difficult, since patients frequently receive antibiotics and antipyretics in the setting of the fever and constitutional complaints that can accompany EN. Sulfa antibiotics, in particular, commonly appear on lists of the causes of EN, but the only detailed report of this association involved a patient who may have had the EN-like reaction of leprosy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/118\">",
"     118",
"    </a>",
"    ]. Commonly prescribed medications with plausible (but rare) associations with EN include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/119,120\">",
"     119,120",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/121-125\">",
"     121-125",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. One patient developed EN following exposure to two different leukotriene receptor antagonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Leprosy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leprosy is an important cause of EN in certain parts of the world. One series of 60 patients with EN reported 8 percent as secondary to leprosy, but did not indicate whether or not any patients presented with EN in advance of an established diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate disorder, erythema nodosum leprosum, may occur in patients with leprosy and may represent an immune complex or hypersensitivity reaction. Unlike typical EN, the skin lesions of erythema nodosum leprosum frequently form pustules and ulcerate as shown in the picture (",
"    <a class=\"graphic graphic_picture graphicRef58875 \" href=\"UTD.htm?40/22/41313\">",
"     picture 3",
"    </a>",
"    ). A large review of patients with leprosy documented 6 percent of patients as exhibiting erythema nodosum leprosum at the time of diagnosis, in addition to occurrences later in the course of established disease, and also in reaction to antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/130\">",
"     130",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link&amp;anchor=H2780058#H2780058\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Type 2 reaction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23305?source=see_link&amp;anchor=H310298210#H310298210\">",
"     \"Treatment and prevention of leprosy\", section on 'Type 2 reaction (T2R, erythema nodosum leprosum, ENL)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) appears in many differential diagnostic lists for EN, but reports of this association are very rare. One case series mentions two patients with recurrent EN and \"elevated auto-antibodies\" who received the diagnosis of \"SLE variants,\" but no other clinical details are provided (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/6\">",
"     6",
"    </a>",
"    ]. Three large cohort studies describing the clinical and serological features of SLE did not report a single occurrence of EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/131-133\">",
"     131-133",
"    </a>",
"    ]. One report does describe two patients found to meet diagnostic criteria for SLE after presenting with panniculitis; the skin lesions resembled typical EN in one of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Other vasculitides or connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the clinical case series report EN as result of a vasculitis or connective tissue disease (CTD) other than Beh&ccedil;et&rsquo;s disease. One pathological series of patients with inflammatory nodules of the legs reported",
"    <span class=\"nowrap\">",
"     2/134",
"    </span>",
"    patients with cutaneous periarteritis nodosa and",
"    <span class=\"nowrap\">",
"     1/134",
"    </span>",
"    patients with Churg-Strauss syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/25\">",
"     25",
"    </a>",
"    ]. Other CTDs that may rarely cause EN include Takayasu's arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/125,135\">",
"     125,135",
"    </a>",
"    ], relapsing polychondritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/136,137\">",
"     136,137",
"    </a>",
"    ], and granulomatosis with polyangiitis (Wegener&rsquo;s) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Dermatophytic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial fungal (dermatophytic) infection was listed as the cause of EN in one patient in the table (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/1\">",
"     1",
"    </a>",
"    ], as well as in one other series of patients with EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/31\">",
"     31",
"    </a>",
"    ]. Another report describes five cases in which EN appeared in the context of documented Trichophyton infection and, in several cases, rechallenge with Trychophyton antigen reproduced a lesion of EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Dental infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental infection has rarely been reported in the literature as a cause of EN. The case series from Egypt mentioned above cites one case of EN as attributable to dental infection, but provides no details for the case [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/30\">",
"     30",
"    </a>",
"    ]. A report from Germany describes four patients with EN fairly convincingly attributable to periodontitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recent extraction of frankly infected teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;No case series has specifically examined EN in human immunodeficiency virus (HIV) infection, but two reports describe HIV-positive patients with EN in the setting of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/141,142\">",
"     141,142",
"    </a>",
"    ], and one German article describes EN in an HIV-positive patient in the absence of any other apparent cause [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is found only on older differential diagnostic lists for EN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/144\">",
"     144",
"    </a>",
"    ]. However, the association still exists as a variant of secondary syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/145,146\">",
"     145,146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Cat-scratch disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with cat-scratch disease, due to infection with Bartonella henselae, EN is an uncommon finding. In one study of 841 patients in Israel a history of cat-scratch disease and confirmatory serologic evidence of B henselae infection, the overall incidence of EN was 2.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/147\">",
"     147",
"    </a>",
"    ]. However, among those with articular involvement the incidence of EN was 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unexplained association with Sweet syndrome has been noted in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/148-150\">",
"     148-150",
"    </a>",
"    ], and appeared in two of the patients in the recent Spanish series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/17\">",
"     17",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 1",
"    </a>",
"    ). The Spanish series also reported one case due to Brucella abortus, previously reported as a cause of EN in case reports only. The series from New York and Singapore each reported one case of gonorrhea. Other case report level causes of EN include a panoply of infectious diseases (references in the case series from France [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/3\">",
"     3",
"    </a>",
"    ]), and granulomatous mastitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/151-153\">",
"     151-153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;EN is usually self-limited or resolves with treatment of the underlying disorder. Thus, treatment is typically symptomatic.",
"   </p>",
"   <p>",
"    Treatment with antibiotics is generally not warranted in patients with EN thought related to streptococcal infection, if such suspicion is based solely upon serological evidence of recent streptococcal infection or a positive throat culture in the absence of symptomatic pharyngitis. Because EN reflects an immune response, and is not a symptom of active infection, giving antibiotics in the context of EN is comparable to treating an asymptomatic throat culture, which has benefit only in limited circumstances. Additionally, in published case series, most patients who develop EN in the context of possible antecedent streptococcal infection have done well without antibiotic treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relief of the discomfort associated with the eruption itself or the accompanying arthralgias can be accomplished with a variety of treatments, including nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/154\">",
"     154",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (360 to 900 mg daily in three divided doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/87,155-157\">",
"     87,155-157",
"    </a>",
"    ]. Potassium iodide as a treatment for EN was \"rediscovered\" after reports of treatment successes with other forms of panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/52/13130/abstract/158,159\">",
"     158,159",
"    </a>",
"    ] that had in turn been suggested by the common use of iodide by turn of the century dermatologists. The basis for the documented benefit of potassium iodide in treating EN is unclear.",
"   </p>",
"   <p>",
"    The evidence for efficacy of pharmacologic treatment for EN is based almost exclusively on small observational studies, making treatment recommendations difficult. Choices of agent, dose, and duration thus remain matters of style and preference for the individual clinician.",
"   </p>",
"   <p>",
"    Glucocorticoids are usually not necessary for idiopathic EN. The decision to use glucocorticoids represents a matter for individual clinical judgment. In considering glucocorticoids, clinicians must weigh the desire to hasten symptomatic relief (eg, in the face of prominent constitutional complaints, extensive, tender skin lesions, or prominent arthritis) against the possibility of masking an underlying neoplastic, inflammatory, or infectious condition (with TB the obvious worst case scenario).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=see_link\">",
"     \"Patient information: Erythema nodosum (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461643711\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painful, erythematous nodules typically develop on the anterior surfaces of both legs, though occasionally elsewhere, and evolve into bruise-like lesions that resolve without scarring over a two- to eight-week period (",
"      <a class=\"graphic graphic_picture graphicRef80056 \" href=\"UTD.htm?8/46/8943\">",
"       picture 1",
"      </a>",
"      ). Histologically, EN is a panniculitis involving inflammation of septa in the subcutaneous fat tissue. Polyarthralgia, fever, and malaise frequently accompany the eruption, and the erythrocyte sedimentation rate is often elevated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of this disorder is most often clinical, with biopsy required only in atypical cases. When biopsy is obtained, it is crucial to obtain a deep incisional biopsy. Diagnostic testing should include a complete blood count and differential, liver enzymes, serum creatinine and urea nitrogen, an antistreptolysin-O titer at diagnosis and two to four weeks later, a chest radiograph, and skin testing for tuberculosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous eruptions that can be confused with EN include other forms of panniculitis, especially nodular vasculitis, subcutaneous infections due to bacteria or fungi, superficial thrombophlebitis, and cutaneous vasculitides. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Nodular vasculitis (erythema induratum)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous conditions have been associated with EN (",
"      <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"       table 1",
"      </a>",
"      ). The diagnosis most frequently associated with EN is streptococcal pharyngitis; however, EN is also frequently idiopathic, and EN may precede other manifestations of diseases associated with EN by months to years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Causes of erythema nodosum'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Dominant causes of EN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of disorders may present with EN and hilar adenopathy (",
"      <a class=\"graphic graphic_table graphicRef53745 \" href=\"UTD.htm?3/27/3515\">",
"       table 2",
"      </a>",
"      ). Sarcoidosis is the classic disorder in this category. Others include tuberculosis, coccidioidomycosis, histoplasmosis, Hodgkin lymphoma, chlamydophila infection, yersiniosis, and blastomycosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Erythema nodosum with hilar adenopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of disorders may present with EN in combination with gastrointestinal complaints (",
"      <a class=\"graphic graphic_table graphicRef78442 \" href=\"UTD.htm?1/44/1739\">",
"       table 3",
"      </a>",
"      ). These include inflammatory bowel disease, Behcet&rsquo;s disease, bacterial gastroenteritides, pancreatitis, and Whipple&rsquo;s disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Erythema nodosum accompanied by gastrointestinal complaints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other conditions associated with EN include pregnancy and oral contraceptives, other medications, leprosy, systemic rheumatic diseases and vasculitides, and infections. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Other conditions associated with EN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EN is usually self-limited or resolves with treatment of the underlying disorder. Thus, treatment is typically symptomatic. Treatment with antibiotics is generally not warranted in patients with EN thought related to streptococcal infection, if such suspicion is based solely upon serological evidence of recent streptococcal infection or a positive throat culture in the absence of symptomatic pharyngitis. Glucocorticoids are usually not necessary for idiopathic EN. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/1\">",
"      Macpherson P. A survey of erythema nodosum in a rural community between 1954 and 1968. Tubercle 1970; 51:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/2\">",
"      Erez A, Horowitz J, Sukenik S. Erythema nodosum in the Negev area--a survey of 50 patients. Isr J Med Sci 1987; 23:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/3\">",
"      Cribier B, Caille A, Heid E, Grosshans E. Erythema nodosum and associated diseases. A study of 129 cases. Int J Dermatol 1998; 37:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/4\">",
"      Hannuksela M. Erythema Nodosum. Ann Clin Res 1971; 3(suppl 7):4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/5\">",
"      Gonz&aacute;lez-Gay MA, Garc&iacute;a-Porr&uacute;a C, Pujol RM, Salvarani C. Erythema nodosum: a clinical approach. Clin Exp Rheumatol 2001; 19:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/6\">",
"      Blomgren SE. Conditions associated with erythema nodosum. N Y State J Med 1972; 72:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/7\">",
"      JAMES DG. Erythema nodosum. Br Med J 1961; 1:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/8\">",
"      VESEY CM, WILKINSON DS. Erythema nodosum: a study of seventy cases. Br J Dermatol 1959; 71:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/9\">",
"      F&ouml;rstr&ouml;m L, Winkelmann RK. Acute panniculitis: a clinical and histopathologic study of 34 cases. Arch Dermatol 1977; 113:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/10\">",
"      Puavilai S, Sakuntabhai A, Sriprachaya-Anunt S, et al. Etiology of erythema nodosum. J Med Assoc Thai 1995; 78:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/11\">",
"      Soderstrom RM, Krull EA. Erythema nodosum. A review. Cutis 1978; 21:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/12\">",
"      Hannuksela M. Erythema nodosum. Clin Dermatol 1986; 4:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/13\">",
"      Schneider JW, Jordaan HF, Geiger DH, et al. Erythema induratum of Bazin. A clinicopathological study of 20 cases and detection of Mycobacterium tuberculosis DNA in skin lesions by polymerase chain reaction. Am J Dermatopathol 1995; 17:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/14\">",
"      Baselga E, Margall N, Barnadas MA, et al. Detection of Mycobacterium tuberculosis DNA in lobular granulomatous panniculitis (erythema induratum-nodular vasculitis). Arch Dermatol 1997; 133:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/15\">",
"      Tan SH, Tan BH, Goh CL, et al. Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids. Int J Dermatol 1999; 38:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/16\">",
"      Winkelmann RK, F&ouml;rstr&ouml;m L. New observations in the histopathology of erythema nodosum. J Invest Dermatol 1975; 65:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/17\">",
"      Garc&iacute;a-Porr&uacute;a C, Gonz&aacute;lez-Gay MA, V&aacute;zquez-Caruncho M, et al. Erythema nodosum: etiologic and predictive factors in a defined population. Arthritis Rheum 2000; 43:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/18\">",
"      Tierney LM Jr, Schwartz RA. Erythema nodosum. Am Fam Physician 1984; 30:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/19\">",
"      Black MM. Panniculitis. J Cutan Pathol 1985; 12:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/20\">",
"      Patterson JW, Brown PC, Broecker AH. Infection-induced panniculitis. J Cutan Pathol 1989; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/21\">",
"      Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol 2001; 45:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/22\">",
"      Requena L, S&aacute;nchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol 2001; 45:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/23\">",
"      Niemi KM, F&ouml;rstr&ouml;m L, Hannuksela M, et al. Nodules on the legs. A clinical, histological and immunohistological study of 82 patients representing different types of nodular panniculitis. Acta Derm Venereol 1977; 57:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/24\">",
"      Sanz Vico MD, De Diego V, S&aacute;nchez Yus E. Erythema nodosum versus nodular vasculitis. Int J Dermatol 1993; 32:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/25\">",
"      Cho KH, Kim YG, Yang SG, et al. Inflammatory nodules of the lower legs: a clinical and histological analysis of 134 cases in Korea. J Dermatol 1997; 24:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/26\">",
"      Kostman JR, DiNubile MJ. Nodular lymphangitis: a distinctive but often unrecognized syndrome. Ann Intern Med 1993; 118:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/27\">",
"      Psychos DN, Voulgari PV, Skopouli FN, et al. Erythema nodosum: the underlying conditions. Clin Rheumatol 2000; 19:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/28\">",
"      Tay YK. Erythema nodosum in Singapore. Clin Exp Dermatol 2000; 25:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/29\">",
"      GORDON H. Erythema nodosum. A review of one hundred and fifteen cases. Br J Dermatol 1961; 73:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/30\">",
"      el-Zawahry M. Erythema nodosum: a study of 60 cases. Int J Dermatol 1971; 10:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/31\">",
"      Fernandes NC, Maceira J, Muniz Mde M. Erythema nodosum: prospective study of 32 cases. Rev Inst Med Trop Sao Paulo 1994; 36:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/32\">",
"      Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/33\">",
"      Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. II. Course and prognosis. Sarcoidosis 1990; 7:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/34\">",
"      Olive KE, Kataria YP. Cutaneous manifestations of sarcoidosis. Relationships to other organ system involvement, abnormal laboratory measurements, and disease course. Arch Intern Med 1985; 145:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/35\">",
"      Edmondstone WM, Wilson AG. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest 1985; 79:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/36\">",
"      Bambery P, Behera D, Gupta AK, et al. Sarcoidosis in north India: the clinical profile of 40 patients. Sarcoidosis 1987; 4:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/37\">",
"      Gupta SK, Gupta S. Sarcoidosis in India: a review of 125 biopsy-proven cases from eastern India. Sarcoidosis 1990; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/38\">",
"      Smith C, Feldman C, Reyneke J, et al. Sarcoidosis in Johannesburg--a comparative study of black and white patients. S Afr Med J 1991; 80:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/39\">",
"      Pietinalho A, Ohmichi M, Hiraga Y, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/40\">",
"      Kremer JM. Histologic findings in siblings with acute sarcoid arthritis: association with the B8,DR3 phenotype. J Rheumatol 1986; 13:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/41\">",
"      Ma&ntilde;&aacute; J, G&oacute;mez-Vaquero C, Montero A, et al. L&ouml;fgren's syndrome revisited: a study of 186 patients. Am J Med 1999; 107:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/42\">",
"      Glenn&aring;s A, Kvien TK, Melby K, et al. Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome. Br J Rheumatol 1995; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/43\">",
"      Gran JT, B&oslash;hmer E. Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature. Scand J Rheumatol 1996; 25:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/44\">",
"      Winterbauer RH, Belic N, Moores KD. Clinical interpretation of bilateral hilar adenopathy. Ann Intern Med 1973; 78:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/45\">",
"      Carr PL, Singer DE, Goldenheim P, et al. Noninvasive testing of asymptomatic bilateral hilar adenopathy. J Gen Intern Med 1990; 5:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/46\">",
"      Collis WR. ERYTHEMA NODOSUM. Br Med J 1933; 2:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/47\">",
"      Mert A, Ozaras R, Tabak F, Ozturk R. Primary tuberculosis cases presenting with erythema nodosum. J Dermatol 2004; 31:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/48\">",
"      Body BA. Cutaneous manifestations of systemic mycoses. Dermatol Clin 1996; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/49\">",
"      Lonky SA, Catanzaro A, Moser KM, Einstein H. Acute coccidioidal pleural effusion. Am Rev Respir Dis 1976; 114:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/50\">",
"      Drutz DJ, Catanzaro A. Coccidioidomycosis. Part II. Am Rev Respir Dis 1978; 117:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/51\">",
"      Einstein HE. Bilateral hilar adenopathy. Ann Intern Med 1973; 78:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/52\">",
"      Arsura EL, Kilgore WB, Ratnayake SN. Erythema nodosum in pregnant patients with coccidioidomycosis. Clin Infect Dis 1998; 27:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/53\">",
"      Ozols II, Wheat LJ. Erythema nodosum in an epidemic of histoplasmosis in Indianapolis. Arch Dermatol 1981; 117:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/54\">",
"      SELLERS TF Jr, PRICE WN Jr, NEWBERRY WM Jr. AN EPIDEMIC OF ERYTHEMA MULTIFORME AND ERYTHEMA NODOSUM CAUSED BY HISTOPLASMOSIS. Ann Intern Med 1965; 62:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/55\">",
"      Medeiros AA, Marty SD, Tosh FE, Chin TD. Erythema nodosum and erythema multiforme as clinical manifestations of histoplasmosis in a community outbreak. N Engl J Med 1966; 274:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/56\">",
"      Thornberry DK, Wheat LJ, Brandt KD, Rosenthal J. Histoplasmosis presenting with joint pain and hilar adenopathy. \"Pseudosarcoidosis\". Arthritis Rheum 1982; 25:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/57\">",
"      Atanes A, G&oacute;mez N, Aspe B, et al. [Erythema nodosum: a study of 160 cases]. Med Clin (Barc) 1991; 96:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/58\">",
"      Bohn S, B&uuml;chner S, Itin P. [Erythema nodosum: 112 cases. Epidemiology, clinical aspects and histopathology]. Schweiz Med Wochenschr 1997; 127:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/59\">",
"      Chalmers RJ, Proctor SJ, Marks JM. Erythema nodosum and Hodgkin's disease. Br J Dermatol 1982; 106:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/60\">",
"      Simon S, Azevedo SJ, Byrnes JJ. Erythema nodosum heralding recurrent Hodgkin's disease. Cancer 1985; 56:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/61\">",
"      Reverter JC, Coca A, Font J, Ingelmo M. Erythema nodosum and pulmonary solitary nodule as the first manifestations of a non-Hodgkin's lymphoma. Br J Dis Chest 1987; 81:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/62\">",
"      Thomson GT, Keystone EC, Sturgeon JF, Fornasier V. Erythema nodosum and non-Hodgkin's lymphoma. J Rheumatol 1990; 17:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/63\">",
"      Taillan B, Ferrari E, Fuzibet JG, et al. Erythema nodosum and Hodgkin's disease. Clin Rheumatol 1990; 9:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/64\">",
"      Navarro JT, Ribera JM, Vaquero M, et al. Erythema nodosum as a presenting feature of T-cell-rich B-cell lymphoma. Ann Hematol 1995; 70:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/65\">",
"      Hannuksela M. Erythema nodosum migrans. Acta Derm Venereol 1973; 53:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/66\">",
"      de Almeida Prestes C, Winkelmann RK, Su WP. Septal granulomatous panniculitis: comparison of the pathology of erythema nodosum migrans (migratory panniculitis) and chronic erythema nodosum. J Am Acad Dermatol 1990; 22:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/67\">",
"      Sarner M, Wilson RJ. Erythema nodosum and psittacosis: report of five cases. Br Med J 1965; 2:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/68\">",
"      Sharma OP. Erythema nodosum and psittacosis pneumonia. A report of an unusual clinical association. Indian J Dermatol 1970; 16:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/69\">",
"      Kousa M, Saikku P, Kanerva L. Erythema nodosum in chlamydial infections. Acta Derm Venereol 1980; 60:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/70\">",
"      Erntell M, Ljunggren K, Gadd T, Persson K. Erythema nodosum--a manifestation of Chlamydia pneumoniae (strain TWAR) infection. Scand J Infect Dis 1989; 21:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/71\">",
"      Sundel&ouml;f B, Gnarpe H, Gnarpe J. An unusual manifestation of Chlamydia pneumoniae infection: meningitis, hepatitis, iritis and atypical erythema nodosum. Scand J Infect Dis 1993; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/72\">",
"      Marie I, Lecomte F, Levesque H, et al. L&ouml;fgren's syndrome as the first manifestation of acute infection due to Chlamydia pneumoniae: a prospective study. Clin Infect Dis 1999; 28:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/73\">",
"      Myhre EB, M&aring;rdh PA. Unusual manifestations of Chlamydia trachomatis infections. Scand J Infect Dis Suppl 1982; 32:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/74\">",
"      Gottlieb LS, Southgate MT. Acute adenopathy in a young man. JAMA 1973; 224:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/75\">",
"      Marchand C, Granier F, Cetre JC, et al. [Anal lymphogranuloma venereum with erythema nodosa. Apropos of a case]. Ann Dermatol Venereol 1987; 114:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/76\">",
"      Mygind N, Thulin H. Yersinia enterocolitica: a new cause of erythema nodosum. Br J Dermatol 1970; 82:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/77\">",
"      Debois J, Vandepitte J, Degreef H. Yersinia enterocolitica as a cause of erythema nodosum. Dermatologica 1978; 156:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/78\">",
"      Olson DN, Finch WR. Reactive arthritis associated with Yersinia enterocolitica gastroenteritis. Am J Gastroenterol 1981; 76:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/79\">",
"      Baert F, Knockaert D, Bobbaers H. Bilateral hilar lymphadenopathy associated with Yersinia enterocolitica infection. Clin Infect Dis 1994; 19:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/80\">",
"      SMITH JG Jr, HARRIS JS, CONANT NF, SMITH DT. An epidemic of North American blastomycosis. J Am Med Assoc 1955; 158:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/81\">",
"      Miller DD, Davies SF, Sarosi GA. Erythema nodosum and blastomycosis. Arch Intern Med 1982; 142:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/82\">",
"      Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/83\">",
"      Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/84\">",
"      Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/85\">",
"      Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol 2005; 19:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/86\">",
"      Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985; 80:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/87\">",
"      Marshall JK, Irvine EJ. Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide. Can J Gastroenterol 1997; 11:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/88\">",
"      Tolia V, Abdullah A, Thirumoorthi MC, Chang CH. A case of Behcet's disease with intestinal involvement due to Crohn's disease. Am J Gastroenterol 1989; 84:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/89\">",
"      Masugi J, Matsui T, Fujimori T, Maeda S. A case of Beh&ccedil;et's disease with multiple longitudinal ulcers all over the colon. Am J Gastroenterol 1994; 89:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/90\">",
"      Kallinowski B, N&ouml;ldge G, Stiehl A. Crohn's disease with Beh&ccedil;et's syndrome like appearance: a case report. Z Gastroenterol 1994; 32:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/91\">",
"      Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis. Med Clin North Am 1998; 82:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/92\">",
"      Chajek T, Fainaru M. Beh&ccedil;et's disease. Report of 41 cases and a review of the literature. Medicine (Baltimore) 1975; 54:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/93\">",
"      Pipitone N, Boiardi L, Olivieri I, et al. Clinical manifestations of Beh&ccedil;et's disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol 2004; 22:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/94\">",
"      Frayha RA, Nasr FW. Erythema nodosum-arthopathy complex as an initial presentation of Beh&ccedil;et's disease. Report of five cases. J Rheumatol 1978; 5:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/95\">",
"      Mizushima Y. Beh&ccedil;et's disease. Curr Opin Rheumatol 1991; 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/96\">",
"      Scott BB. Salmonella gastroenteritis--another cause of erythema nodosum. Br J Dermatol 1980; 102:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/97\">",
"      Eastmond CJ. Gram-negative bacteria and B27 disease. Br J Rheumatol 1983; 22:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/98\">",
"      Grossman ME, Katz B. Salmonella enteritidis enterocolitis: another cause of diarrhea and erythema nodosum. Cutis 1984; 34:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/99\">",
"      Lauhio A, Repo H, Nyberg M, L&auml;hdevirta J. Erythema nodosum and conjunctivitis triggered by enteritis due to Salmonella typhimurium. Scand J Infect Dis 1988; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/100\">",
"      Steckelberg JM, Terrell CL, Edson RS. Laboratory-acquired Salmonella typhimurium enteritis: association with erythema nodosum and reactive arthritis. Am J Med 1988; 85:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/101\">",
"      Shrivastava A, Thistlethwaite D. Erythema nodosum and arthritis with Salmonella enteritidis enteritis. Br J Dermatol 1993; 128:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/102\">",
"      Thomson BJ, Nuki G. Erythema nodosum following typhoid vaccination. Scott Med J 1985; 30:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/103\">",
"      Lambert M, Marion E, Coche E, Butzler JP. Campylobacter enteritis and erythema nodosum. Lancet 1982; 1:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/104\">",
"      Galeazzi M, Palombi L, Mancinelli S, et al. Campylobacter infections and erythema nodosum. Eur J Epidemiol 1986; 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/105\">",
"      Neithercut WD, Hudson MA, Smith CC. Can erythema nodosum and reactive arthritis be a sequel to Shigella flexneri gastroenteritis? Scott Med J 1984; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/106\">",
"      Tami LF. Erythema nodosum associated with Shigella colitis. Arch Dermatol 1985; 121:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/107\">",
"      Hannuksela M, Ahvonen P. Skin manifestations in human yersiniosis. Ann Clin Res 1975; 7:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/108\">",
"      MAYORAL JW, GOMPERTZ ML, YOUNG JM. Subcutaneous fat necrosis associated with pancreatitis and portal cirrhosis; report of a case. Gastroenterology 1959; 36:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/109\">",
"      Schrier RW, Melmon KL, Fenster LF. Subcutaneous nodular fat necrosis in pancreatitis. Arch Intern Med 1965; 116:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/110\">",
"      Mullin GT, Caperton EM Jr, Crespin SR, Williams RC Jr. Arthritis and skin lesions resembling erythema nodosum in pancreatic disease. Ann Intern Med 1968; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/111\">",
"      Kwee D, Fields JP, King LE Jr. Subcutaneous Whipple's disease. J Am Acad Dermatol 1987; 16:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/112\">",
"      HOLCOMB FD. ERYTHEMA NODOSUM ASSOCIATED WITH THE USE OF AN ORAL CONTRACEPTIVE. REPORT OF A CASE. Obstet Gynecol 1965; 25:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/113\">",
"      Baden HP, Holcomb FD. Erythema nodosum from oral contraceptives. Arch Dermatol 1968; 98:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/114\">",
"      Langer R, Bukovsky I, Lipshitz I, et al. Erythema nodosum associated with pregnancy. Case reports. Eur J Obstet Gynecol Reprod Biol 1979; 9:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/115\">",
"      Salvatore MA, Lynch PJ. Erythema nodosum, estrogens, and pregnancy. Arch Dermatol 1980; 116:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/116\">",
"      Yang SG, Han KH, Cho KH, Lee AY. Development of erythema nodosum in the course of oestrogen replacement therapy. Br J Dermatol 1997; 137:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/117\">",
"      Bombardieri S, Munno OD, Di Punzio C, Pasero G. Erythema nodosum associated with pregnancy and oral contraceptives. Br Med J 1977; 1:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/118\">",
"      Nishioka Sde A, Goulart IM, Burgarelli MK, et al. Necrotizing erythema nodosum leprosum triggered by cotrimoxazole? Int J Lepr Other Mycobact Dis 1994; 62:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/119\">",
"      Beutler M, Hartmann K, Kuhn M, Gartmann J. Arthralgias and omeprazole. BMJ 1994; 309:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/120\">",
"      Ricci RM, Deering KC. Erythema nodosum caused by omeprazole. Cutis 1996; 57:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/121\">",
"      Maggiore G, Grifeo S, Marzani MD. Erythema nodosum and hepatitis B virus (HBV) infection. J Am Acad Dermatol 1983; 9:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/122\">",
"      Di Giusto CA, Bernhard JD. Erythema nodosum provoked by hepatitis B vaccine. Lancet 1986; 2:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/123\">",
"      Goolsby PL. Erythema nodosum after Recombivax HB hepatitis B vaccine. N Engl J Med 1989; 321:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/124\">",
"      Rogerson SJ, Nye FJ. Hepatitis B vaccine associated with erythema nodosum and polyarthritis. BMJ 1990; 301:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/125\">",
"      Castresana-Isla CJ, Herrera-Martinez G, Vega-Molina J. Erythema nodosum and Takayasu's arteritis after immunization with plasma derived hepatitis B vaccine. J Rheumatol 1993; 20:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/126\">",
"      Kellett JK, Beck MH, Chalmers RJ. Erythema nodosum and circulating immune complexes in acne fulminans after treatment with isotretinoin. Br Med J (Clin Res Ed) 1985; 290:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/127\">",
"      Joly P, Prost C, Gaudemar M, Revuz J. [Acne fulminans triggered by isotretinoin therapy]. Ann Dermatol Venereol 1991; 118:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/128\">",
"      Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/129\">",
"      Dellaripa PF, Wechsler ME, Roth ME, Drazen J. Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents. Mayo Clin Proc 2000; 75:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/130\">",
"      Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev 1994; 65:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/131\">",
"      Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/132\">",
"      Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996; 135:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/133\">",
"      Fong KY, Thumboo J, Koh ET, et al. Systemic lupus erythematosus: initial manifestations and clinical features after 10 years of disease. Ann Acad Med Singapore 1997; 26:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/134\">",
"      Ajubi N, Nossent JC. Panniculitis as the first manifestation of systemic lupus erythematosus: description of two cases. Neth J Med 1993; 42:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/135\">",
"      Franc&egrave;s C, Boisnic S, Bl&eacute;try O, et al. Cutaneous manifestations of Takayasu arteritis. A retrospective study of 80 cases. Dermatologica 1990; 181:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/136\">",
"      McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/137\">",
"      Rauh G, Kamilli I, Gresser U, Landthaler M. Relapsing polychondritis presenting as cutaneous polyarteritis nodosa. Clin Investig 1993; 71:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/138\">",
"      Barksdale SK, Hallahan CW, Kerr GS, et al. Cutaneous pathology in Wegener's granulomatosis. A clinicopathologic study of 75 biopsies in 46 patients. Am J Surg Pathol 1995; 19:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/139\">",
"      Hicks JH. Erythema nodosum in patients with tinea pedis and onychomycosis. South Med J 1977; 70:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/140\">",
"      Kirch W, D&uuml;hrsen U. Erythema nodosum of dental origin. Clin Investig 1992; 70:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/141\">",
"      Fegueux S, Maslo C, de Truchis P, et al. Erythema nodosum in HIV-infected patients. J Am Acad Dermatol 1991; 25:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/142\">",
"      Narvaez J, Rodriguez-Moreno J, Clavaguera MT, Campoy E. Tuberculous erythema nodosum in patients with human immunodeficiency virus infection. Rev Rhum Engl Ed 1996; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/143\">",
"      Hohl D, Gueissaz F, G&eacute;rain J, Frenk E. [Erythema nodosum and AIDS]. Hautarzt 1992; 43:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/144\">",
"      L&ouml;fgren S. The concept of erythema nodosum revised. Scand J Respir Dis 1967; 48:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/145\">",
"      Alinovi A, Lui P, Benoldi D. Syphilis--still a cause of erythema nodosum. Int J Dermatol 1983; 22:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/146\">",
"      Silber TJ, Kastrinakis M, Taube O. Painful red leg nodules and syphilis: a consideration in patients with erythema nodosum-like illness. Sex Transm Dis 1987; 14:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/147\">",
"      Giladi M, Maman E, Paran D, et al. Cat-scratch disease-associated arthropathy. Arthritis Rheum 2005; 52:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/148\">",
"      Sitjas D, Puig L, Cuatrecasas M, De Moragas JM. Acute febrile neutrophilic dermatosis (Sweet's syndrome). Int J Dermatol 1993; 32:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/149\">",
"      Wilkinson SM, Heagerty AH, English JS. Acute febrile neutrophilic dermatosis in association with erythema nodosum and sarcoidosis. Clin Exp Dermatol 1993; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/150\">",
"      Cuende Quintana E, G&oacute;mez Rz de Mendarozqueta M, Gorospe Arrazuria MA, et al. Concurrent Sweet's syndrome and L&ouml;fgren's syndrome. J Rheumatol 1996; 23:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/151\">",
"      Adams DH, Hubscher SG, Scott DG. Granulomatous mastitis--a rare cause of erythema nodosum. Postgrad Med J 1987; 63:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/152\">",
"      Donn W, Rebbeck P, Wilson C, Gilks CB. Idiopathic granulomatous mastitis. A report of three cases and review of the literature. Arch Pathol Lab Med 1994; 118:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/153\">",
"      Gonz&aacute;lez-Gay MA, Garc&iacute;a-Porr&uacute;a C, Iba&ntilde;ez D, Garc&iacute;a-Pa&iacute;s MJ. Osteoarticular complications of brucellosis in an Atlantic area of Spain. J Rheumatol 1999; 26:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/154\">",
"      Ubogy Z, Persellin RH. Suppression of erythema nodosum by indomethacin. Acta Derm Venereol 1982; 62:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/155\">",
"      Schulz EJ, Whiting DA. Treatment of erythema nodosum and nodular vasculitis with potassium iodide. Br J Dermatol 1976; 94:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/156\">",
"      Horio T, Imamura S, Danno K, Ofuji S. Potassium iodide in the treatment of erythema nodosum and nodular vasculitis. Arch Dermatol 1981; 117:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/157\">",
"      Horio T, Danno K, Okamoto H, et al. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol 1983; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/158\">",
"      AGUADE JP, PINOL J, VILANOVA X. [Subacute migrating nodular hypodermitis]. Ann Dermatol Syphiligr (Paris) 1956; 83:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/52/13130/abstract/159\">",
"      PERRY HO, WINKELMANN RK. SUBACUTE NODULAR MIGRATORY PANNICULITIS. Arch Dermatol 1964; 89:170.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5612 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13130=[""].join("\n");
var outline_f12_52_13130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H461643711\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Nodular vasculitis (erythema induratum)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CAUSES OF ERYTHEMA NODOSUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dominant causes of EN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Streptococcal pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Erythema nodosum with hilar adenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Chlamydophila infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Yersiniosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Erythema nodosum accompanied by gastrointestinal complaints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Behcet's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Bacterial gastroenteritides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Whipple's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other conditions associated with EN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Pregnancy and oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Leprosy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Other vasculitides or connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Dermatophytic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Dental infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Cat-scratch disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461643711\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5612\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5612|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/46/8943\" title=\"picture 1\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/46/32484\" title=\"picture 2\">",
"      Septal panniculitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/22/41313\" title=\"picture 3\">",
"      Erythema nodosum leprosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5612|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/8/35981\" title=\"table 1\">",
"      Differential dx E nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/27/3515\" title=\"table 2\">",
"      E nodosum and hilar adenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/44/1739\" title=\"table 3\">",
"      E nodosum and GI symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28874?source=related_link\">",
"      Pathogenesis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=related_link\">",
"      Patient information: Erythema nodosum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23305?source=related_link\">",
"      Treatment and prevention of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_52_13131="Incidence of heart failure";
var content_f12_52_13131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of heart failure in the Framingham study: 44-year follow-up of cohort and 20-year follow-up of offspring",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Average annual incidence per 1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45 to 54",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55 to 64",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 74",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 to 84",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        85 to 94",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13131=[""].join("\n");
var outline_f12_52_13131=null;
var title_f12_52_13132="Causes pleural eosinophilia";
var content_f12_52_13132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of pleural fluid eosinophilia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Exudative effusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs",
"       </td>",
"       <td>",
"        (See table \"Drug-induced pleural fluid eosinophilia\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Infection",
"       </td>",
"       <td>",
"        Bacteria (eg, parapneumonic effusion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungi (eg, Histoplasma capsulatum, Coccidioides immitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasites (eg, Amebiasis, Ascaria, Dracunculus, Echinococcosis, Filaria, Paragonimus, Strongyloides, Toxocara)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Inflammatory",
"       </td>",
"       <td>",
"        Acute eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic eosinophilic pneumonia&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Churg-Strauss Syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Lymphoma, mesothelioma, metastatic carcinoma&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxin",
"       </td>",
"       <td>",
"        Benign asbestos effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Trauma",
"       </td>",
"       <td>",
"        Hemothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracentesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Transudative effusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13132=[""].join("\n");
var outline_f12_52_13132=null;
var title_f12_52_13133="MPM II";
var content_f12_52_13133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mortality prediction model II (MPM II)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Variable",
"      </td>",
"      <td class=\"subtitle1\">",
"       Response",
"      </td>",
"      <td class=\"subtitle1\">",
"       Points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patient age*",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Medical or unscheduled surgical admission?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Cardiopulmonary resuscitation prior to admission?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <p>",
"        Coma (Glasgow coma scale 3-5)?",
"       </p>",
"       <p>",
"        (Does not include patients whose coma is due to overdose or who received neuromuscular blocking agents)",
"       </p>",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Heart rate &ge;150 bpm?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Systolic blood pressure &le;90 mmHg?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Mechanical ventilation?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <p>",
"        Acute renal failure?",
"       </p>",
"       <p>",
"        (Does not include pre-renal azotemia)",
"       </p>",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Cardiac dysrhythmias?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Cerebrovascular accident?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Intracranial mass effect?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Gastrointestinal bleeding?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <p>",
"        Metastatic carcinoma?",
"       </p>",
"       <p>",
"        (Distant metastases only; does not include local lymph node involvement)",
"       </p>",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Cirrhosis?",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <p>",
"        Chronic renal insufficiency?",
"       </p>",
"       <p>",
"        (Creatinine &gt;2 mg/dL chronically)",
"       </p>",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patient age does not receive points when calculating the severity score; however, it is used in the formula to calculate predicted mortality.",
"     <br>",
"      &bull; Excluded patients include the &lt;18 years old, burn patients, coronary care patients, and cardiac surgery patients.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lemeshow, S, Teres, D, Klar, J, et al. Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993; 270:2478.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13133=[""].join("\n");
var outline_f12_52_13133=null;
var title_f12_52_13134="Cervical spine clinical clearance algorithm";
var content_f12_52_13134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical spine clinical clearance algorithm*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 493px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This algorithm applies to children who are able to converse, can convey accurately the presence or absence of numbness, weakness, or other neurologic symptoms, and remember the event.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Down syndrome, Klippel Feil syndrome, Morquio syndrome, Larsen syndrome, prior cervical spine injury, or cervical spine surgery.",
"      <br>",
"       &Delta; High speed motor vehicle collision, bicycle injury, diving or other activity with hyperextension or hyperflexion of neck, falls greater than body height, and other acceleration-deceleration injuries of the head.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13134=[""].join("\n");
var outline_f12_52_13134=null;
var title_f12_52_13135="Apical 4 chamber color Doppler systole";
var content_f12_52_13135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four chamber view with color flow Doppler during systole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view with color flow Doppler was obtained from a normal subject during systole. The systolic flow signal is shown in blue, ie, flow is moving away from the transducer. This signal is used to position a pulsed wave Doppler sample volume in the left ventricular outflow tract (LVOT) so that flow characteristics can be quantitated.",
"    <div class=\"footnotes\">",
"     LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_52_13135=[""].join("\n");
var outline_f12_52_13135=null;
